G protein-coupled receptor allosterism and complexing by Kenakin, Terry & Christopoulos, Arthur
G Protein-Coupled Receptor Allosterism and
Complexing
ARTHUR CHRISTOPOULOS AND TERRY KENAKIN
Department of Pharmacology, University of Melbourne, Parkville, Victoria, Australia (A.C.); and 7TM Pharmacology Systems Research,
Glaxo Smith-Kline Research and Development, Research Triangle Park, North Carolina (T.K.)
This paper is available online at http://pharmrev.aspetjournals.org
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 323
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 324
II. Allosteric receptor models of G protein-coupled receptors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
A. Historical perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
1. Cooperativity in binding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
2. Allosteric transitions: multistate models of receptor action . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
3. Allosteric interactions: ternary complex models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
B. Behavior of the ternary complex model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 332
C. The molecular nature of allosterism at G protein-coupled receptors . . . . . . . . . . . . . . . . . . . . . . 333
1. G protein-specific receptor conformations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334
2. Ligand-specific receptor conformations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336
III. Detecting allosteric interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 338
A. Assays of radioligand binding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 338
1. Equilibrium binding assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 338
2. Inhibition binding assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339
3. Nonequilibrium (kinetic) studies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344
B. Assays of receptor function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348
1. Schild analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348
2. Additivity of concentration ratios . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348
3. Pharmacological resultant analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 350
C. Potential pitfalls. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351
IV. Usefulness of allosteric modulators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 352
V. Location of the allosteric site(s). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 354
A. Locks and keys . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 354
B. Modulation by ions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355
C. Interactions at the receptor-G protein interface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 356
D. Extracellular allosteric sites . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 357
1. Multiple allosteric sites. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359
VI. Endogenous allosteric modulators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 360
VII. G protein-coupled receptor complexing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361
A. Receptor-receptor interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362
B. Accessory proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 364
VIII. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368
Abstract——G protein-coupled receptors (GPCRs)
represent the largest family of cell-surface receptors.
These receptors are natural allosteric proteins be-
cause agonist-mediated signaling by GPCRs requires a
conformational change in the receptor protein trans-
mitted between two topographically distinct binding
sites, one for the agonist and another for the G protein.
It is now becoming increasingly recognized, however,
that the agonist-bound GPCR can also form ternary
complexes with other ligands or “accessory” proteins
and display altered binding and/or signaling proper-
ties in relation to the binary agonist-receptor complex.
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Allosteric sites on GPCRs represent novel drug targets
because allosteric modulators possess a number of
theoretical advantages over classic orthosteric li-
gands, such as a ceiling level to the allosteric effect
and a potential for greater GPCR subtype-selectivity.
Because of the noncompetitive nature of allosteric
phenomena, the detection and quantification of such
effects often relies on a combination of equilibrium
binding, nonequilibrium kinetic, and functional sig-
naling assays. This review discusses the development
and properties of allosteric receptor models for
GPCRs and the detection and quantification of alloste-
ric effects. Moreover, we provide an overview of the
current knowledge regarding the location of possible
allosteric sites on GPCRs and candidate endogenous
allosteric modulators. Finally, we discuss the poten-
tial for allosteric effects arising from the formation of
GPCR oligomers or GPCRs complexed with accessory
cellular proteins. It is proposed that the study of allo-
steric phenomena will become of progressively
greater import to the drug discovery process due to
the advent of newer and more sensitive GPCR screen-
ing technologies.
I. Introduction
A general property of all receptors is the ability to
interact with their endogenous ligands (hormones and
neurotransmitters) to alter cellular responsiveness
without changing the chemical nature of the ligand. This
is in contrast to enzymes, where oftentimes a substrate
is made to bind in an energetically unfavorable mode
that leads to its eventual modification. G protein-cou-
pled receptors (GPCRs) constitute the largest superfam-
ily of receptors and, not surprisingly, mediate the ma-
jority of transmembrane signal transduction in living
cells. These receptors respond to a wide range of rela-
tively small and structurally diverse chemicals such as
biogenic amines, peptides, hormones, and even light
with global changes in receptor conformation that then
lead to larger scale protein-protein interactions.
Traditionally, the unifying feature of GPCRs has been
their interaction with G protein(s) to transduce stimuli
imparted to the receptor from the extracellular environ-
ment to the intracellular response machinery of the cell.
Implicit in this mechanism, therefore, is the fact that the
intracellular contact points on the GPCR recognized by
the G protein are necessarily distinct from the extracel-
lular domains used by endogenous ligands. The lateral
translocation of GPCRs in the cell membrane to interact
with their cognate G protein(s) is the best known exam-
ple of GPCR-protein interaction, but it is by no means
the only such example, because additional protein cou-
pling partners are now being rapidly identified for the
GPCR superfamily (vide infra). The entire surface of a
GPCR can be considered a potential binding site for
biologically active molecules, both proteins and small
molecules such as drugs. It is a major premise of this
review that a tripartite system composed of a ligand, a
GPRC, and an additional GPCR coupling partner repre-
sents a general motif for ligand action at GPCRs extend-
ing beyond the G protein example. In other words, the
requisite interaction between topographically distinct
binding sites on a GPCR to effect change in cellular
function identifies these receptors as natural allosteric
proteins.
Drugs have traditionally been discovered through the
screening of numerous chemical structures on a biolog-
ical system. The greater the number of structures tested,
the greater is the probability of detecting a biologically
active ligand. Throughout this process, it is clear that
the type of receptor screen employed to detect biologi-
cally active molecules will greatly define the types of
molecules detected. Thus, if the tracer molecule in the
screen is a radioligand, then the ligands most readly
detected by that screen will be those that obstruct the
access of the radioligand to its specific binding site.
Notably, the current emphasis away from radioligand
binding and toward high throughput functional screen-
ing is beginning to reveal ligands that can change bio-
logical function without exerting apparent effects on
radioligand binding. It is possible that such ligands are
not interacting with the classic, agonist-binding domain
of the receptor but rather with other topographically
distinct domains.
This raises an interesting philosophical point in drug
discovery, namely the current paucity of allosteric li-
gands in the known population of biologically active
molecules. On one hand it could be assumed that this
paucity reflects their relative unimportance and rarity
in chemical space. However, another point of view would
suggest that this paucity reflects the bias imposed on the
drug screening process through the use of radioligand
binding. As outlined above, the need for high throughput
screening has, in the past, required radioligand binding
assays to achieve the required volume of sampling of
chemical space for drug discovery. However, the im-
proved technology of functional screening in the new
millennium will certainly test the potential effects of
1 Abbreviations: GPCR, G protein-coupled receptor; ICI-174,864,
N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH; NalBzOH, naloxone benzoyl-
hydrazone; PI, phosphoinositide; CTC, cubic ternary complex; ETC,
extended ternary complex; QCM, quaternary complex model; CHA,
N6-cyclohexyladenosine; MIA, methylisobutylamiloride; EPA, 5-(N-
ethyl-N-isopropyl)-amiloride; W84, hexane-1,6-bis-(dimethyl-3-
pthalimidopropyl) ammonium bromide; MPEP, 2-methyl-6-(phenyl-
ethynyl)-pyridine; RAMP, receptor activity modifying protein;
CRLR, calcitonin receptor-like receptor; HEK, human embryonic
kidney; IP, inositol phosphate; CHO, Chinese hamster ovary; 5-HT,
5-hydroxytryptamine; GABA, -aminobutyric acid; TM, transmem-
brane; mGluR, metabotropic glutamate; QNB, quinuclidinyl benzi-
late; NMS, N-methylscopolamine; THA, tetrahydroaminacridine;
CGRP, calcitonin gene-related peptide; TCM, ternary complex
model.
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this bias because the throughput available for functional
testing in reporter, yeast, and melanophore systems now
equals and in many cases surpasses that of radioligand
binding. In turn, this increased screening capability
should cause an increase in the texture of biologically
active molecules detected. Whereas, before 1995, the
primary chemical targets were agonists, partial ago-
nists, and antagonists, the availability of functional
screens should allow the detection of new classes of
drugs. For example, allosteric enhancers potentiate the
effects of agonists either through enhancement of ago-
nist affinity, stabilization of agonist/receptor and G pro-
tein interaction or other unspecified enhancement of
efficacy (vide infra). Similarly, allosteric modulators
could block agonist stimulation of the receptor without
necessarily interfering with agonist binding to the re-
ceptor. Allosteric agonists could activate receptors with-
out being subject to appreciable blockade by classic an-
tagonists. This review will discuss examples of these
types of ligands and the different manifestations of al-
losterism at GPCRs.
II. Allosteric Receptor Models of G Protein-
Coupled Receptors
A. Historical Perspective
Most of the theoretical framework associated with the
study of ligand-receptor interactions was developed in
the first half of the twentieth century, when very little
was known about the actual identity of receptors them-
selves. By borrowing from studies in the field of enzyme
kinetics, pharmacologists and physiologists adopted the
law of mass action as a minimal mechanistic descriptor
of the interaction between a ligand and its receptor.
Often, the simplest form of the mass action model—a
reversible, saturable, one-to-one interaction between li-
gand and receptor—was deemed compatible with exper-
imental observations. Even today, where much has been
accomplished in terms of identifying the proteinaceous
nature and molecular properties of the major receptor
families, the starting point for the qualitative or quan-
titative analysis of drug-receptor data remains the con-
cept of the drug interacting at a “primary” binding site
recognized by agonists and competitive antagonists.
The classical view of ligand-receptor interactions
mentioned above has served pharmacologists faithfully
in studies of receptor mechanisms, classification, and
drug discovery, yet as early as the 1930s one of the
pioneers of analytical pharmacology, A. J. Clark (1937),
postulated the existence of a “complex receptor with
which one drug can unite without displacing the other
drug”. In an extensive treatise on drug-receptor theory,
Arie¨ns et al. (1956) formalized and extended Clark’s
speculation by developing a mathematical model for a
noncompetitive interaction between “a substance A and
a receptor system R, the latter being partly inactivated
or sensitized as a result of the interaction of a substance
B with another receptor system”. In Arie¨ns’ model, both
“receptor systems” were considered to be interdepen-
dent, “possibly representing two distinct active loci on
the one protein molecule”. In a similar vein, Van den
Brink (1969) coined the term “metaffinoid antagonism”
to define potential drug-receptor interactions where a
change in the binding site of the antagonist led to a
change in the binding site of the agonist, resulting in a
subsequent reduction in agonist affinity for its receptor.
Hence, the concept of cross-interactions between the
agonist binding site and other potentially distinct bind-
ing domains on receptors was a relatively early, albeit
mainly theoretical, component of classic receptor theory,
alongside the better-known and by far better-studied
concept of competitive drug-receptor interactions (Gad-
dum, 1936; Arunlakshana and Schild, 1959; Kenakin,
1997c).
Much of the early drug-receptor theory was developed
to describe the behavior of receptors that would later be
identified as GPCRs. Unfortunately, detailed mechanis-
tic studies on these receptors were initially hampered by
the fact that the requisite dissociation of the ligand-
receptor binding process from the subsequent signal
transduction events that characterize GPCR activity
meant that there were no sufficiently detailed tools with
which to dissect drug actions at these receptors at the
molecular level. This meant that for some time, drug-
GPCR theory remained largely operational. In contrast,
early studies of enzymes and voltage- and ligand-gated
ion channels did not suffer from the same drawbacks as
their GPCR counterparts and, thus, the two most impor-
tant mechanistic insights that led directly to the current
models of allosterism at GPCRs were derived from the
enzyme and ion channel arena.
1. Cooperativity in Binding. The first important de-
velopment in allosteric theory came from experimental
evidence indicating that more than one molecule of li-
gand was able to bind to certain enzymes or ion channels
to effect a change in the properties of the protein, a
phenomenon termed “cooperativity”. In fact, the well
known Hill equation commonly used nowadays to em-
pirically fit concentration-response data was originally
derived to describe cooperative binding (Hill, 1910). Fig-
ure 1 illustrates two classic examples of cooperative
binding proteins, the enzyme hemoglobin and the
GABAA ion channel-receptor complex. Simple mass-ac-
tion kinetics predict that the binding of a single molecule
of ligand to a single binding site on a protein would yield
a hyperbolic isotherm (when plotted on a linear scale)
with a slope coefficient equal to unity. However, the
binding of oxygen to hemoglobin (Fig. 1A) or GABA to
the GABAA receptor (Fig. 1B) are characterized by dis-
tinctly sigmoid curves when plotted on a linear scale,
reflecting the multiple equivalents of ligand binding to
the same protein complex. Studies such as these con-
ducted on a variety of ion channel-linked receptors, thus,
led to the conclusion that certain receptors can possess
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more than one binding site for ligands. This concept
invoked another phenomenon that was also originally
described in the field of enzymology, that is, the idea of
allosteric (or allotopic) binding sites.
The term “allosteric” (from the Greek meaning “other
site”) was first used by Monod and Jacob (1961) and
subsequently defined by Monod et al. (1963) in a paper
describing the ability of enzymes to have their biological
activity modified, in either a positive or negative fash-
ion, by the binding of ligands to sites that were topo-
graphically distinct from the substrate-binding site.
Monod et al. (1963) defined these accessory binding sites
as allosteric sites, in contrast to the substrate-binding
(active) site, which was defined as the isosteric site. In
their original paper, Monod et al. (1963) outlined three
general classes of interactions between two ligands on
the one enzyme molecule. Class I interactions repre-
sented classic competition, where the substrate and in-
hibitor competed for overlapping regions on the receptor.
Class II interactions were deemed to encompass situa-
tions where an inhibitor could form an attachment with
a region of the enzyme not recognized by the substrate
while some of the inhibitor molecule could interact with
the substrate-binding site in a competitive manner. An
example of this type of “direct interaction” nowadays is
the effect of the “captive agonist” salmeterol at the 2-
adrenoceptor, where the long alkyl side chain of the
molecule forms a persistent attachment with the recep-
tor that allows its salbutamol-like active moiety to in-
teract with the classic agonist binding domain to yield a
persistent response (see Coleman et al., 1996). The final
type of interaction (class III) was termed “indirect” or
“allosteric”. These interactions arise when the binding of
a ligand to the allosteric site induces a conformational
change in the protein and modulates the binding of the
substrate to the isosteric site, and vice versa. The bio-
logical activity of the enzyme was subsequently assumed
to arise from the modified properties of the substrate-
binding site, and not through a direct effect of the allo-
steric modulator itself. Monod et al. (1963) referred to
this conformational change in the enzyme as an alloste-
ric transition, although that term has since come to
encompass a slightly different concept (see below).
With regards to receptor proteins, the primary bind-
ing site recognized by the endogenous agonist or hor-
mone is conceptually equivalent to an enzyme’s isosteric
site, and has been referred to as the orthosteric site
(Proska and Tucek, 1994; Christopoulos, 2002). Any
binding site on a receptor protein that is able to modu-
late the binding properties of the orthosteric site by
mediating a conformational change in the receptor may
be classed as an allosteric site. Hence, many of the
cooperative interactions that had been reported for ion
channel-linked receptors in the literature in the past,
such as the binding of two acetylcholine molecules to a
single nicotinic acetylcholine receptor (Galzi et al., 1991)
or the binding of two GABA molecules to a GABAA
receptor (Sigel and Buhr, 1997), are also allosteric inter-
actions because the binding of one equivalent of ligand
actually alters the affinity of the subsequent binding of
the next equivalent(s) of ligand.
2. Allosteric Transitions: Multistate Models of Recep-
tor Action. Before discussing allosteric mechanisms in
greater detail, it is necessary to address some of the
issues that have arisen in the past regarding the termi-
nology applied to allosteric proteins (Table 1). The term
“allosteric” has been used by a number of authors in
different ways, and this has led to some confusion in the
literature as to what it actually means (e.g., see
Colquhoun, 1998). Nowadays, it seems that a distinction
is necessary between the terms “allosteric interaction”
and “allosteric transition”. For the purposes of this re-
view, an allosteric interaction is defined as an interac-
tion that occurs between two (or more) topographically
distinct binding sites on the same receptor complex. The
essential features of a simple allosteric interaction are
FIG 1. Cooperative binding in enzymes and ion channel-linked recep-
tors. A, the binding of oxygen to hemoglobin dimers (curve D, Hill slope 
1) and tetramers (curve T, Hill slope  3.3). Concentrations of hemoglo-
bin range from 40 nM (D) to 100 M (T). Data taken from Ackers et al.
(1992). B, conductance change at the crustacean neuromuscular junction
produced by -aminobutyric acid (GABA). Redrawn from Colquhoun
(1973) based on data of Takeuchi and Takeuchi (1969).
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as follows: (a) The binding sites are not overlapping, that
is, there is no mutual exclusivity in binding. (b) The
binding of one ligand to its site affects the binding of the
second ligand at the other site and vice versa. Allosteric
interactions are, thus, reciprocal in nature. (c) The effect
of an allosteric modulator can be either negative or
positive with respect to the binding and/or function of an
orthosteric ligand.
Although Monod et al. (1963) initially defined the
conformational change in protein structure associated
with an allosteric interaction as an allosteric transition,
they subsequently presented a more formalized model of
allosteric proteins that gave rise to the second major
development in allosteric theory, namely, an emphasis
away from interactions occurring between sites to inter-
actions occurring between conformational states (Monod
et al., 1965). Allosteric proteins were then described by
these authors as follows: (a) They are oligomeric in na-
ture (i.e., composed of more than one subunit). (b) Each
subunit possesses one (equivalent) binding site for li-
gand, thus, giving rise to cooperative interactions. (c)
They can exist as an equilibrium mixture of two or more
states in the absence of ligand, with the transition be-
tween states now being defined as the allosteric transi-
tion. (d) The transition between conformational states
involves a conservation of molecular symmetry such
that all subunits “flip” from one state to another in a
concerted fashion. (e) Ligands that prefer binding to one
state over another will “select” the preferred state and,
thus, increase the proportion of proteins in that state. As
a consequence, observed (macroscopic) ligand affinity
will alter depending on the type and amount of confor-
mational state that predominates.
It can be seen that this last definition of allosteric
proteins is quite explicit. Its description of interactions
between multiple subunits makes it immediately appli-
cable to oligomeric proteins that display cooperative
binding, e.g., ion channel-linked receptors. It should be
noted that models dealing with receptor isomerization
between different conformational states were published
as early as the 1950s to describe the postulated mecha-
nism of action of the nicotinic acetylcholine receptor (del
Castillo and Katz, 1957; Katz and Thesleff, 1957), al-
though the actual term allosteric was not coined until
the subsequent work of Monod and colleagues (1963). An
important property of receptor models that incorporate
allosteric transitions between conformational states is
the prediction of receptor activity in the absence of li-
gand as a consequence of the isomerization process, i.e.,
constitutive receptor activity (Karlin, 1967; Colquhoun,
1973; Thron, 1973; Leff, 1995). These models are now
more commonly referred to as “two-state” or “multi-
state” models and represent the simplest mechanism
approximating certain known aspects of protein behav-
ior. In essence, the two-state model of receptor action is
a mechanism of conformational selection, whereby a li-
gand selectively binds to a pre-existing receptor confor-
mation, thereby creating a bias toward that conforma-
tion. In terms of free energy, this mechanism is
generally preferable to one of conformational induction,
where the ligand actually creates the conformation
through the binding process (Burgen, 1981; Kenakin,
1995a). It should be noted, however, that conformational
selection and conformational induction most likely rep-
resent two extremes of a common mechanism used by
proteins in changing the type and abundance of confor-
mational state in the presence of ligand.
On the surface, the concept of receptor allosterism
within the context of multiple conformational equilibria
may seem somewhat removed from the concept of an
interaction occurring between distinct binding sites on
the one protein. For instance, multistate models allow
allosterism to arise simply as a consequence of the tran-
sition between one orthosteric conformation to another,
without necessarily postulating the existence of a second
binding site in each conformational state. In contrast,
the simple model of allosteric interaction between two
sites does not explicitly consider the existence of multi-
ple conformations of the protein on which the sites are
situated. As will be discussed below, these two ideas are
not mutually exclusive; rather they address different
aspects of a protein’s ability to undergo conformational
changes. To avoid engendering further confusion, the
remainder of this review will use the term “receptor
isomerization” when describing the transition of recep-
tors between multiple conformational states and “allo-
steric interaction” when describing a reciprocal interac-
tion between multiple binding sites on the same protein.
3. Allosteric Interactions: Ternary Complex Models. Ion
channels and ion channel-linked receptors are known to
exist as oligomers; that is, they are composed of multiple
protein subunits, and with an increased complexity in
macromolecular structure comes an increased probability
of multiple ligand binding sites. Allosteric interactions at
ion channel-linked receptors, therefore, have been well
documented and studied for almost half a century now. In
contrast, GPCRs have, until recently, been considered tra-
ditionally to exist as monomers, and relatively fewer allo-
TABLE 1
Glossary of terms commonly used in the description of allosteric effects
Term Description
Orthosteric site The agonist binding site on a receptor
Allosteric site An additional binding site on a receptor that
is distinct from the agonist binding site,
but that can modulate receptor activity
Allosteric interaction An interaction between two topographically
distinct binding sites on the same receptor
complex
Allosteric transition The isomerization of a receptor protein
between multiple conformational states
Cooperative binding This term is commonly used to describe the
binding of two or more molecules to the
same receptor; however, its strict
definition is the binding of more than one
molecule of the same ligand to a receptor
complex.
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steric interactions occurring at GPCRs have been identi-
fied relative to ion channel-linked receptors. Nevertheless,
it is now apparent that orthosteric ligand binding at
GPCRs can be subject to allosteric modulation by other
ligands or other proteins.
The best known example of an allosteric modulator of
ligand binding to GPCRs is the G protein itself, and, as
with the original formulation of allosteric theory in re-
lation to enzymes and ion channels, the development of
the current allosteric models for GPCRs was also based
on two major ideas. The first idea was the development
of two-state theory for ion channels and ion channel-
linked receptors, as described above (del Castillo and
Katz, 1957; Katz and Thesleff, 1957; Karlin, 1967;
Colquhoun, 1973; Thron, 1973; Leff, 1995). These mod-
els described how selective affinity of ligands for specific
receptor states (in the case of either open or shut ion
channels) could bias the system toward the favored
state. The second major idea in the GPCR field was that
receptors could translocate within membranes and as-
sociate with other membrane-bound proteins (Cuatreca-
sas, 1974). Thus, any mechanism ascribed to a GPCR
would need to explicitly invoke the presence of at least
two binding sites on the same receptor protein, one for
the orthosteric ligand and one for the G protein. This
tripartite coupling mechanism represents the simplest
scheme for an allosteric interaction occurring between
distinct sites (as opposed to states) on a single receptor
protein.
In general, the interaction between agonist binding
and G protein coupling is positively cooperative in na-
ture (Ehlert, 1985). This is logical, given the mecha-
nisms that are thought to underlie signaling via GPCRs
(Gilman, 1987; Bourne, 1997; Hamm, 1998). Agonist
binding to the orthosteric site results in an alteration of
receptor conformation that displays a higher affinity
toward the G protein, thus favoring coupling. However,
the binding of GTP to its site on the G protein results in
a change of G protein structure that is transmitted to
the receptor’s conformation as a negatively cooperative
effect on agonist binding, thus promoting the uncoupling
of the activated G protein from the receptor and allowing
signaling to proceed. These negatively cooperative ef-
fects of GTP on agonist binding underlie the so-called
“GTP shift” that has often been used as a biochemical
measure of agonist efficacy (Kenakin, 1997c; Christo-
poulos and El-Fakahany, 1999).
Figure 2 summarizes the evolution of GPCR models
from simple operational schemes to the contemporary
ternary complex mechanisms. The original TCM, as de-
scribed by De Lean et al. (1980) allowed a ligand-bound
activated receptor to form a G protein complex resulting
in activation. This is a simple example of a receptor
isomerization mechanism, where the binding of ligand A
promotes a conformation of receptor that either signals
in its own right (e.g., ion-channels; Fig. 2A, left) or
couples to and activates a G protein (Fig. 2A, right). The
next level of progression toward present GPCR models
also involved the incorporation of different receptor con-
formations into the GPCR scheme. This latter develop-
ment owed much to the introduction of recombinant
receptor systems into receptor pharmacology, because it
allowed for the ability to control the stoichiometry be-
tween receptors and G proteins. With this capability
came the discovery of constitutive GPCR activity due to
the spontaneous coupling of receptors in active confor-
mations to G proteins in the absence of ligands. For this
to occur, the minimal receptor model for such a system is
shown in Fig. 2B (left). In the figure, L is the isomeriza-
tion constant defining the equilibrium between active
(R*) and inactive (R) receptor states, Ka is the equilib-
rium association constant of the ligand-receptor complex
and  is referred to as a “cooperativity factor”, i.e., it is a
ratio of the affinity of the ligand for the active versus the
inactive state of the receptor. Alternatively, it may be
viewed as a measure of the ability of ligand-bound re-
ceptor to enrich the R* state. The use of cooperativity
factors in closed equilibrium reaction schemes such as
those shown in Fig. 2 serves to reduce the number of
parameters required to describe a model while satisfying
the principle of microscopic reversibility (Wyman and
Allen, 1951; Weber, 1975; Wyman, 1975; Ehlert, 1985;
Weiss et al., 1996a). This idea, also referred to as the
concept of “free energy coupling” (Weber, 1972, 1975),
states that the energy required to reach one species from
another must be the same at equilibrium, irrespective of
what path is chosen, hence, the use of the cooperativity
factor .
When developing the original TCM, De Lean et al.
(1980) also considered the possibility of a closed (cyclic)
system operating in equilibrium, that is, they speculated
about the existence of precoupled RG complexes in the
absence of bound ligand (Fig. 2B, right). However, direct
evidence for this phenomenon was lacking at the time
and had to be inferred from the analysis of complex
radioligand binding isotherms. Nevertheless, the pro-
posal of a requisite ternary complex mechanism to ac-
count for the known behavior of GPCRs paved the way
for further explorations into the properties of such a
model (Wregget and De Lean, 1984; Ehlert, 1985). Im-
portantly, the symmetry of the model allowed it to be
equally applicable to situations where more than one
type of drug molecule could occupy the receptor at the
same time (Stockton et al., 1983; Ehlert, 1988). Obser-
vations made initially on studies of the actions of a
series of hexamethonium derivatives and the neuromus-
cular blocking agent gallamine on muscarinic acetylcho-
line receptors had already suggested that such a mech-
anism may be operative (Lu¨llman et al., 1969; Clark and
Mitchelson, 1976; Stockton et al., 1983). Thus, the si-
multaneous binding of an orthosteric ligand, A, and an
allosteric ligand, B, to the receptor would be governed by
the respective equilibrium association constants, Ka and
Kb, just like the binding of an orthosteric ligand and G
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FIG 2. The evolution of allosteric receptor models for GPCRs. The earliest models were based on the assumption that the law of mass action dictates
the binding of ligand A to the receptor, R, according to the equilibrium association constant, Ka, and then subsequently resulted in a response. This
operational approach was then impacted upon by a progression of mechanistic insights. A, the agonist bound receptor can isomerize to produce a
different state that can signal on its own (left) or translocate within the membrane to interact with a G protein (right). B, the receptor, R, can
spontaneously isomerize to an active state, R*, (left) or couple to a G protein, G, or allosteric ligand, B, (right) in the absence or presence of orthosteric
ligand. Thermodynamic considerations dictate that the isomerization constant, L, and the equilibrium association constants, Ka, Kb, and Kg, are
modified to an extent governed by the cooperativity factors, , , or , when the same interactions take place on an occupied receptor. C, the ETC model
of Samama et al. (1993) combines the two-state model with the ternary complex model but only allows for the active receptor state to interact with
G protein. D, the CTC model (left) of Weiss et al. (1996a, 1996b, 1996c) allows the inactive R state to interact with G protein and the active state. This
model is formally identical with the allosteric two-state model (right) of Hall (2000), which describes the interaction of an allosteric modulator and
orthosteric ligand on a receptor that can adopt active and inactive conformations.
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protein would be governed by the constants Ka and Kg
(Fig. 2B, right). As before with the closed two-state
model, the thermodynamic requirement of reversibility
also adds cooperativity factors to the affinities between
receptor, orthosteric ligand, and allosteric ligand () or G
protein () in the full ternary complex model. Interest-
ingly, this principle is common in most applications of
allosteric theory and stems from the idea that, as de-
scribed by Sir Francis Bacon in 1620 “it is certain that
all bodies whatsoever have perception”; in terms of the
ternary complex model for receptors, if a receptor species
is bound to some other species in the system, then it
cannot be considered identical with its unbound coun-
terpart. For example, if the receptor is bound to ligand,
its affinity for G protein is Kg not Kg. If it is bound to
another ligand, B, then its affinity for agonist is Ka and
not Ka. This form of the TCM was the first explicit model
of allosteric interactions occurring between topographi-
cally distinct binding sites applied to a GPCR, and it is
still a useful, minimal model with which to assess and
quantify experimental data (vide infra). It should be
noted, however, that the TCM as an allosteric model of
receptor-G protein interactions, on one hand, and recep-
tor-modulator interactions, on the other, can lead to
different predictions with respect to the binding curve of
the orthosteric ligand. This is because G protein acces-
sibility to receptors within the plane of the membrane
can often be limiting, leading to shallow and/or biphasic
orthosteric ligand binding curves due to G protein de-
pletion (see Ehlert, 1985). In contrast, allosteric modu-
lator drugs, like orthosteric ligands, are invariably
present in vast excess relative to the concentration of
receptor, and ligand depletion is, thus, much less likely
to occur; the simple TCM does not predict biphasic or
shallow binding curves in the absence of ligand deple-
tion (vide infra).
The subsequent conclusive demonstration of constitu-
tive GPCR activity by Costa and Herz (1989) indicated
that receptors could couple to and activate G proteins in
the absence of ligand. This necessitated the modification
of the original TCM described by De Lean et al. (1980),
which did not have the capability of spontaneous forma-
tion of the R*G species, into the extended ternary com-
plex model (ETC model; Samama et al., 1993), as is
shown in Fig. 2C. From this scheme, it can be seen that
the amount of active-state receptor available for subse-
quent coupling to G protein is given by the isomerization
constant L. Therefore, increasing the relative stoichiom-
etry of receptors versus G protein leads to an elevated
abundance of R*G, the species responsible for agonist
independent response (constitutive receptor activity).
For example, for a system containing 1000 receptors and
a value for L of 0.001, there will be one single R* species.
However, if the receptor number were to be increased by
a factor of 1000, then the number of receptors in the
signaling R*G form would be 1000. By increasing the
number of receptors present in the system, the number
of spontaneously active receptors can be increased until
a threshold is attained where the resulting response
from the spontaneously formed R*G species can be ob-
served. The ETC model was, thus, the first GPCR model
to explicitly incorporate allosteric transitions between
receptor states (e.g., governed by L and ) and allosteric
interactions between multiple binding sites (e.g., gov-
erned by  and ).
Although the ETC model went beyond the original
ternary complex model to accommodate experimental
findings, it is thermodynamically incomplete. Again,
this is directly related to the principle of free energy
coupling described above, and has culminated in the
development of the more thermodynamically complete,
albeit more complex, cubic ternary complex (CTC) model
by Weiss et al. (1996a–c; Fig. 2D, left). Although the
CTC model is formally more correct than the ETC
model, this correctness comes at a price of carrying too
many parameters to allow for useful estimation based on
experimental observations. In turn, this can make the
model less predictive. Therefore, in practical terms, it is
worth considering whether the more complex CTC
model is worth applying to experimental data instead of
the ETC model. The critical issue is the need for the
ARG complex, the nonsignaling ternary complex be-
tween ligand, receptor, and G protein.
There are two approaches that can be used to try to
determine which model, ETC or CTC, has greater utility
in the receptor pharmacology of GPCR systems. One is
the biochemical evaluation of the evidence for the exis-
tence of the inactive ARG complex. To date, there is a
paucity of such evidence but it is not clear whether this
is because of the apparent rarity of this species in bio-
logical systems or because of the lack of tools for detect-
ing this species. There are isolated cases where experi-
mental data are consistent with the existence of a
nonsignaling ternary complex species. One example in-
volves the inverse agonist ICI-174,864 (N,N-diallyl-Tyr-
Aib-Aib-Phe-Leu-OH) acting at the Gi/o-coupled -opioid
receptor expressed in HEK 293 cells (Chiu et al., 1996).
Whereas the opioid agonist DPDPE mediated an inhibi-
tion of forskolin-stimulated cAMP accumulation, ICI-
174,864 caused a further stimulation of the cAMP re-
sponse above the basal forskolin response, consistent
with the inverse agonist properties previously ascribed
to ICI-174,864 (Costa and Herz, 1989). However, pre-
treatment of the cells with pertussis toxin, which uncou-
ples Gi/o-proteins from their receptors, resulted in an
abolition of both the agonistic effects of DPDPE and the
inverse agonist effects of ICI-174,864. Although the
former finding is consistent with the expectation that
agonists require active receptor-G protein complexes,
the latter finding with ICI-174,864 is inconsistent with
the notion that inverse agonists prefer uncoupled recep-
tor-G protein complexes to promote a reduction in con-
stitutive receptor activity. One explanation for the per-
tussis toxin sensitivity of the ICI-174,864 effect is the
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possibility that this particular inverse agonist attenu-
ates constitutive receptor activity not by uncoupling re-
ceptor-G protein complexes, but rather by promoting a
stable ARG complex that is unable to signal.
Another example of a possible nonsignaling ARG ter-
nary complex involves the cannabinoid CB1 receptor,
where the inverse agonist N-(piperidino-1-yl)-5-(4-chloro-
phenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3-car-
boxamide decreased constitutive receptor activity (as mea-
sured by activation of mitogen-activated protein kinase)
according to standard inverse agonist kinetics for the re-
ceptor but also, unexpectedly, blocked the pertussis toxin-
sensitive activation of the same kinase by insulin (Fig. 3A)
and insulin-like growth factor 1 receptors (Bouaboula et
al., 1997). The crossover inhibition was dependent on the
presence of the CB1 receptor and did not occur with the
non-GPCR, fibroblast growth-factor receptor. Crossover in-
hibition was also observed when Mas-7 (a mastoparan
analog) was used to directly activate Gi/o proteins and
suggests that G protein “trapping” was operative through
the interaction between SR141716A and CB1 receptors to
make Gi/o protein inaccessible to other receptor pathways.
This suggests the existence of the nonsignaling ARG spe-
cies in this receptor system.
Similarly, in CHO cells stably transfected with -opi-
oid receptors, there is biochemical evidence of a nonsig-
naling ligand/receptor/G protein complex. In this system
the potent -opioid receptor antagonist naloxone benzo-
ylhydrazone (NalBzOH) blocks agonist-mediated cyclic
AMP responses. However, a 3-fold enhancement of af-
finity was observed for NalBzOH in equilibrium binding
studies in the presence of the stable GTP analog Gp-
p(NH)p. This indicated a low level of negative efficacy
for this ligand at this receptor and also that NalBzOH
has a preferential affinity for the inactive state of the
receptor. In apparent contrast to this, [3H]NalBzOH
demonstrated biphasic kinetics indicative of two affinity
states (Fig. 3B), consistent with an association of at least
one state with G protein (Brown and Pasternak, 1998).
An association with G protein (with no concomitant sig-
naling) was indicated by the elimination of the high
affinity state by Gpp(NH)p. The lack of a similar effect
by the -opioid antagonist diprenorphine and the pro-
duction of this same effect with pertussis toxin treat-
ment indicated that the high-affinity component was a
ligand-specific receptor complex associated with Gi/o pro-
tein.
Most recently, a study by Chen et al. (2000a) provided
strong evidence for the potential of a mammalian GPCR
to inhibit signaling in a dominant-negative manner by
sequestering G protein -subunits in a nonsignaling ter-
nary complex. Specifically, a point mutation in Phe303
in the sixth transmembrane domain of the 1b-adreno-
ceptor resulted in a receptor that displayed enhanced
agonist binding affinity relative to the wild type, but a
loss in agonist-mediated signaling through the phospho-
inositide (PI) pathway. Furthermore, the mutant recep-
tor, but not the wild type, could be coimmunoprecipi-
tated with Gq in the absence of agonist, indicating a
tight coupling of mutant receptor to G protein, and over-
expression of Gq-subunits resulted in a rescue of the
dominant negative activity of the mutant with respect to
PI signaling. Taken together, these findings are compat-
ible with the ability of the mutant 1b-receptor to selec-
tively sequester Gq-subunits in a conformation that
promotes high agonist binding affinity but not signaling.
A second potential method of determining which
model best fits a given experimental system is to exam-
ine the predictions of the models and compare those with
experimental findings. For example, both the ETC and
CTC models predict that increasing the amount of G
protein available to the receptor will increase the
amount of R*G species and, subsequently, the amount of
constitutive activity. The relationship between G pro-
FIG 3. Biochemical evidence for a nonsignaling [ARG] ternary com-
plex. A, interaction of the inverse agonist, SR141716A, with the canna-
binoid CB1 receptor abolishes Gi/o-dependent mitogen-activated protein
kinase signaling mediated by the insulin receptor tyrosine kinase, possi-
bly by sequestering G protein in an inactive ternary complex of inverse-
agonist, CB1 receptor, and G protein. Data taken from Bouaboula et al.
(1997). B, dissociation kinetics of opioids in CHO cell membranes express-
ing the human -opioid receptor. Unlike the antagonist [3H]diprenor-
phine, the antagonist [3H]NalBzOH and the agonist [3H]DAMGO each
displayed biphasic dissociation kinetics, indicative of two affinity states of
the receptor. The biphasic binding was sensitive to guanine nucleotides,
suggesting that both [3H]DAMGO and [3H]NalBzOH were coupling to G
proteins, but only the former agent was able to initiate a response. Data
taken from Brown and Pasternak (1998).
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tein and constitutive activity predicted by the ETC
model is given by (Chen et al., 2000b)
basal
max 
LG
KG
1 
LG
KG
(1)
As can be seen from the above equation, at theoreti-
cally infinite concentrations of G protein, the constitu-
tive activity will reach the system maximal response. A
different relationship is predicted by the CTC model. As
described by Weiss et al. (1996a,b,c), the relationship
between constitutive activity and receptor number, ex-
pressed as a fraction of the maximal system response, is
given by
basal
max 
R
KG
1  L
1  RKG1  L
(2)
If receptor concentration is not limiting (i.e., as [R]3 ),
then the constitutive activity will reach an asymptotic
value of
basal
max 
1  L
1  L (3)
For a high-efficacy agonist,   1 and the expression
reduces to
basal
max 
L
1  L (4)
Due to the possibility of producing a nonsignaling RG
species, the CTC model predicts that the constitutive
activity produced by addition of G protein need not reach
the system maximum.
It can be seen that the two models predict the same
qualitative but differing quantitative responses. Unfor-
tunately, although submaximal levels of constitutive ac-
tivity have been observed with receptor transfection ex-
periments in Xenopus laevis melanophores (Chen et al.,
2000b), it is not possible to determine whether the G
protein levels in these cells were limiting and, thus,
prevented the production of system maximal response.
Also, because cellular responses are amplified functions
of [R*G], it is not possible to determine whether a full
constitutive maximal response relates to a submaximal
or fully maximal conversion of receptor species to R*G.
It is presently unclear which of these models better
predicts and describes experimental findings with
GPCRs. On the practical side, the ETC model has fewer
parameters, is simpler to use, and is, therefore, parsi-
monious. The CTC model is heuristic and more encom-
passing but has a greater number of nonestimatable
parameters. It could be that different systems are better
suited for different models, i.e., there may be GPCR
systems where the ARG is so unimportant as to be
negligible, thereby, making the ETC model preferable,
and other systems where the ARG species plays a role,
thus, necessitating use of the CTC model.
Another application of the CTC model exploits the
symmetry in the model with respect to the reciprocity of
interaction between orthosteric and allosteric sites. If it
is assumed that the ligand occupying the secondary site
on the receptor is not a G protein, but rather an alloste-
ric modulator drug, then the model can be recast to yield
a mathematical description of drug-drug allosteric mod-
ulation between two binding sites on a receptor that
exists in both active and inactive states (see Fig. 2D,
right). The properties of this “allosteric two-state model”
were recently explored by Hall (2000), who compared it
to the CTC model for agonist-G protein interaction. Al-
though the equations derived from the model are for-
mally identical with those of the G protein-based CTC
model, there are important differences between the two
models with respect to the effects of the cooperativity
factors on receptor activation (Hall, 2000). This is be-
cause the allosteric two-state model (Fig. 2D, right)
quantifies response as the production of activated recep-
tor species (R*, AR*, BR*, and AR*B), as would be the
case for ion channel-linked receptors. In contrast, the
CTC model quantifies response as the production of
activated receptor-G protein species (i.e., R*G, AR*G).
Thus, the  parameter in the allosteric two-state model
only modifies orthosteric ligand affinity; the equivalent
parameter in the CTC model, , modifies the ability of
agonist to interact with G and, thus, affects response
production and efficacy. As with the CTC model versus
the ETC model, the applicability of the two-state allo-
steric model will depend on the observations to which it
is applied and the systems in which it is tested. The
allosteric two-state model would be most suitable, for
instance, at ion channel-linked receptors, where the pro-
duction of stimulus is equivalent to production of re-
sponse. One interesting prediction of the model is the
property of coagonism, whereby an allosteric modulator
can modify orthosteric ligand intrinsic efficacy without
itself possessing any efficacy; this is embodied in the
parameter, 	, in Fig. 2D. Coagonism is commonly ob-
served for ligands acting at the NMDA receptor, for
example (Corsi et al., 1996).
B. Behavior of the Ternary Complex Model
Allosteric interactions at GPCRs can be manifested in
a variety of ways. A useful means of obtaining a picture
of the possible repertoire of behaviors displayed by allo-
steric ligands is to simulate them using one of the allo-
steric ternary complex models introduced above and to
compare the predications of the model with experimen-
tal observations. When choosing the most appropriate
model for such an exercise, a trade-off needs to be made
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between number of model parameters and parsimony in
model predictive capabilities. For this reason, the simple
allosteric TCM (e.g., Fig. 2B) remains the most parsimo-
nious and most commonly used model for both prediction
and quantification of allosteric interactions at GPCRs
(Ehlert, 1988; Lazareno and Birdsall, 1995; Christopou-
los, 2000a,b, 2002). At best, the model can be used to
derive actual estimates of cooperativity factors and li-
gand affinities under the appropriate experimental con-
ditions. At worst, it can provide semiquantitative or
operational parameters that can still be useful in system
characterization and/or subsequent experimental de-
sign. Thus, some discussion about the operational be-
havior of the simple allosteric TCM is warranted.
As outlined previously, the simple allosteric TCM at
GPCRs involves the concomitant binding of two ligands,
A and B, to the one receptor, R, to form a ternary com-
plex, ARB. For illustrative purposes, Scheme 1 will be
adopted.
Ligand A binds to the orthosteric site, whereas ligand
B, the allosteric modulator, binds to the allosteric site.
The constants Ka and Kb denote the equilibrium associ-
ation constants for the binding of A and B, respectively,
to their binding sites on the unoccupied receptor. In this
regard, each of these bimolecular reactions is no differ-
ent from the standard mass-action schemes applied to
orthosteric binding. However, allosteric interactions are
not only characterized by unconditional ligand affinity
constants, but also by the cooperativity factor denoted
here by the symbol . Values of   1 denote positive
cooperativity, whereas  	 1 denotes negative cooperat-
ivity. Values of  approaching zero would be indistin-
guishable from competitive antagonism. In contrast, an
 value equal to 1 denotes an allosteric interaction that
results in unaltered ligand affinity at equilibrium. Allo-
steric interactions can still be discerned under nonequi-
librium conditions, and this is discussed later (vide in-
fra).
In addition to the well characterized allosteric effects
between agonists and G proteins occurring at GPCRs, a
growing number of studies are identifying additional
allosteric sites located on specific GPCRs. The best stud-
ied examples involve the muscarinic acetylcholine recep-
tors, with allosteric interactions having been conclu-
sively demonstrated at all five subtypes of these
receptors (Henis et al., 1989; Lee and El-Fakahany,
1991; Tucek and Proska, 1995; see Birdsall et al., 1996;
Ellis, 1997; Christopoulos et al., 1998; Holzgrabe and
Mohr, 1998). However, allosteric interactions between
various ligands have also been demonstrated at other
GPCRs, as shown in Table 2. Although this may seem to
be a rather diverse list of receptors, allosteric interac-
tions at GPCRs share a number of common features that
allow them to be detected and possibly used in a thera-
peutic sense.
From the simple scheme described above, fractional
receptor occupancy by the orthosteric ligand A (
A) is
equal to ([AR] 
 [ARB]/[R]) and is expressed as

A 
A
KA
A
KA

1  B/KB
1  B/KB
(5)
where KA and KB denote the equilibrium dissociation
constants of A and B, respectively, at the free receptor.
In the absence of allosteric modulator, the receptor oc-
cupancy of the orthosteric site is determined by the
orthosteric ligand’s equilibrium dissociation constant,
KA. However, when an allosteric ligand is present, the
occupancy of the orthosteric site will now be determined
by the following composite parameter, KApp
KApp 
KA1  B/KB
1  B/KB
(6)
If the interaction between A and B is positively cooper-
ative (  1), then KApp 	 KA and the binding curve of
ligand A at the modulator-occupied receptor will be
shifted to the left relative to the binding curve of A at the
free receptor. In contrast, negative cooperativity be-
tween A and B ( 	 1) will be manifested as a rightward
displacement of the binding curve for A (i.e., KApp  KA).
Figure 4 illustrates these relationships for the binding of
an orthosteric ligand in the presence of increasing con-
centrations of an allosteric modulator with an  value of
either 0.1 (negative cooperativity) or 10 (positive coop-
erativity). This figure also illustrates an important as-
pect of allosteric interactions, namely that these types of
interactions approach a limit, the extent of which is
governed by the magnitude of . The closer the value of
 is to 1, the more readily the limit is approached with
increasing concentrations of B.
C. The Molecular Nature of Allosterism at G Protein-
Coupled Receptors
The ability of orthosteric ligands, once bound, to mod-
ify the signaling properties of receptors has been defined
as a measure of orthosteric ligand efficacy (Kenakin,SCHEME 1.
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1996a, 2002). The very nature of efficacy is intertwined
with the ability of the orthosteric ligand to produce a
conformation of the receptor that either promotes sig-
naling (as is seen with agonists) or attenuates constitu-
tive receptor signaling (as is observed with inverse ago-
nists). Because the binding of an allosteric modulator to
a distinct accessory site on the receptor causes its own
alteration of receptor conformation, it is conceivable that
the resulting conformation may influence orthosteric li-
gand efficacy, in addition to the effects on orthosteric
ligand affinity described in the preceding section. Thus,
although assays of receptor signaling are necessarily
influenced by post-binding stimulus-response events,
they nevertheless afford the opportunity to detect spe-
cific receptor conformations promoted by allosteric mod-
ulators that may not necessarily be evident in radioli-
gand binding assays.
When considering the conformational space of GPCRs,
it is often parsimonious to confine GPCR activity to two
states (an inactive state that does not activate G pro-
teins and an active state that does). However, there are
no data to suggest that agonists simply enrich a single
population of active receptor state to produce response.
It is well established that proteins exist in numerous
conformations or substates (Frauenfelder et al., 1988,
1991; Frauenfelder, 1995). Thermal energy causes fluc-
tuation between these states with certain low-energy
states being “favored” (Gerstein et al., 1994; Haltia and
Freire, 1995). Although the ETC and CTC models are
sometimes referred to as two-state models, this is a
misnomer from the point of view of ligand activation.
The two states R and R* refer to the unliganded forms of
the receptor, and upon binding of ligand, the factors 
and  (and additionally  for the CTC model) confer
complete ligand specificity to the protein species. Under
these circumstances, these models are infinite-state
models because ligands could have unique values for ,
, and  (Watson et al., 2000). This introduces the con-
cept of G protein- and ligand-selective receptor active
states.
1. G Protein-Specific Receptor Conformations. There
are numerous lines of evidence to suggest that different
agonists produce response through the formation of dif-
ferent receptor active states. The most compelling data
are obtained from receptors that are pleiotropic with
respect to the G proteins with which they interact be-
cause these different G proteins provide a means of
differentiating signaling active states. From this stand-
point, the pattern of activation of various stimulus-re-
sponse pathways can be used to infer the existence of
these states. This phenomenom is termed “stimulus traf-
ficking”, whereby agonists differ in the ability to stimu-
late separate stimulus-response pathways through a
single receptor (Kenakin, 1995a, 1995b, 1997a).
It is known that different regions of the cytosolic loops
of GPCRs activate different G proteins (Ikezu et al.,
1992; Wade et al., 1999), and it would not be expected
that different tertiary conformations of the receptor pro-
tein would expose these different regions in an identical
manner. Therefore, if ligands produce different tertiary
conformations, then these may be detected through the
relative capabilities of the resulting species to activate
different G proteins. This should not be confused with
differential activation of pathways through strength of
TABLE 2
Selected examples of allosteric modulators of GPCRs
Receptor Example Modulator(s) References
Adenosine A1 PD 81,723; PD 117,975 Bruns and Fergus, 1990; Bhattacharya and Linden, 1995;
Kollias-Baker et al., 1997; Musser et al., 1999;
Kourounakis et al., 2001
Adenosine A2A Amilorides Gao and Ijzerman, 2000
Adenosine A3 VU5455 VU8504 Gao et al., 2001
Adrenoceptor 1 Amilorides; Benzodiazepines Waugh et al., 1999; Leppik et al., 2000
Adrenoceptor 2A, 2B Amiloride Nunnari et al., 1987; Wilson et al., 1991; Leppik et al.,
1998; Leppik and Birdsall, 2000
Adrenoceptor 2D Agmatine Molderings et al., 2000
Calcium Sensing Receptor NPS 467; NPS 568; L-amino acids Hammerland et al., 1998; Conigrave et al., 2000b
Chemokine CXCR3 IP-10; I-TAC Cox et al., 2001
Chemokine CCR5, CXCR4 Trichosanthin Zhao et al., 1999
Chemokine CCR1, CCR3 UCB35625 Sabroe et al., 2000
Dopamine D1 Zinc Schetz and Sibley, 1997
Dopamine D2 Amilorides, zinc Hoare and Strange, 1996; Schetz et al., 1999
Endothelin ETA Aspirin, sodium salicylate Blandin et al., 2000; Talbodec et al., 2000
GABAB CGP7930; CGP13501 Urwyler et al., 2001
Glutamate mGluR1 CPCCOEt, Ro 67-7476, Ro 01-6128; BAY36-7620 Litschig et al., 1999; Carroll et al., 2001; Knoflach et al.,
2001
Glutamate mGluR5 MPEP Pagano et al., 2000; Spooren et al., 2001
Muscarinic M1–M5 Gallamine, alcuronium, brucine, dimethyl-W84 Clark and Mitchelson, 1976; Stockton et al., 1983; Knaus
et al., 1991; Proska and Tucek, 1994; Lazareno and
Birdsall, 1995; Traenkle et al., 1998
Neurokinin NK1 Heparin Knaus et al., 1991
Purine P2Y1 2,2-pyridylsatogen tosylate Spedding et al., 1975; King et al., 1996
Serotonin 5-HT1B/1D 5-HT moduline Fillion et al., 1996; Massot et al., 1998
Serotonin 5-HT2A Oleamide Thomas et al., 1997
Serotonin 5-HT7 Oleamide Thomas et al., 1997; Hedlund et al., 1999
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stimulus. If a receptor couples to one pathway with great
efficiency and to another one poorly, a strong agonist
with high efficacy may activate both pathways, whereas
a weaker agonist would activate only the most efficiently
coupled pathway; this is not stimulus trafficking. To
conclude true differences in receptor active state, a re-
versal of potency for the pathways or differences in the
maximal activation of the pathways by the agonists
must be demonstrated. This has been shown for some
receptors. For example, the human 5-HT2C receptor is
coupled to two separate response pathways in CHO
cells, namely phospholipase A2-mediated arachadonic
acid release and phospholipase C-mediated inositol
phosphate accumulation (IP accumulation). There is a
striking reversal in the maximal responses of agonists in
this system that cannot be accommodated by postulating
the production of a single receptor active state. Thus, the
agonist ()-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopro-
pane produces a higher maximal stimulation than the
5-HT agonist quipazine for arachadonic acid release
(Berg et al., 1998). Because efficacy is the sole receptor-
related determinant of maximal response, these data
indicate that ()-1-(2,5-dimethoxy-4-iodophenyl)-2-
aminopropane has a greater efficacy for IP accumulation
than quipazine for arachadonic acid release. This rela-
tive efficacy for these agonists is reversed for IP accu-
mulation where quipazine has the greater efficacy.
Thus, a receptor-related parameter, namely efficacy, re-
verses with the two agonists for the same receptor. Sim-
ilarly, there is a reversal of the relative potency of sub-
stance P analogs on neurokinin NK-1 receptors
described where substance P is 2.1 times more potent
than the analog [P3
Emet(O2)
11]SP for producing cyclic
AMP through NK-1 receptor activation, but is 0.11 times
less potent than the analog for producing phosphoinosi-
tol hydrolysis through activation of the same receptor
(Sagan et al., 1999). Reversals of efficacy also have been
reported for pituitary adenylate cyclase-activating
polypeptide receptors (Spengler et al., 1993), dopamine
receptors (Meller et al., 1992), and Drosophila tyramine
receptors (Robb et al., 1994). In general, these data
cannot accommodate a mechanism whereby all of the
agonists involved produce an identical active receptor
state.
Specially designed recombinant GPCR systems
(termed “stimulus-biased” assay systems; Watson et al.,
2000) also can be used to detect stimulus trafficking.
These systems consist of surrogate host cells for receptor
transfection with identical cellular backgrounds except
for the enrichment of a single G-subunit. A study with
human calcitonin receptor (type 2), a pleiotropic receptor
that can interact with Gs, Gq, and Gi, (Horne et al.,
1994), showed striking reversals in relative potencies of
peptide calcitonin agonists. Specifically, after transfec-
tion of the receptors into wild-type HEK 293 cells and
HEK cells stably transfected with enriched populations
of G-subunits, differences in relative agonist potencies
were observed. For example, the relative potency of por-
cine calcitonin and rat amylin changed by a factor of 18
(from 4.6 to 84) when compared in wild-type and Gs-
enriched cells. This suggests that porcine calcitonin pro-
duces a conformation more conducive to using Gs than
does amylin. In these studies, even the rank order of
potency of the agonists changed in that the potency of
rat calcitonin gene-related peptide (CGRP) was 0.3
times that of rat amylin in wild-type cells and three
times greater than rat amylin in Gs-enriched host cells
(Watson et al., 2000). Because the classification of recep-
tors using agonist potency ratios and rank orders of
potency is based on the tenet that the active state pro-
FIG 4. Effect of a negative allosteric modulator (A), positive allosteric
modulator (B), or a competitive antagonist (C) on orthosteric ligand-
receptor occupancy (
A) based on the simple ternary complex model for
allosteric interactions (eq. 5). For all the simulations, pKA  6 and pKB 
9. The modulator, B, modifies orthosteric ligand affinity to a limit deter-
mined by the cooperativity factor () that characterizes the interaction
between allosteric and orthosteric sites. In these examples, ligand affinity
is either maximally diminished (A) or enhanced (B) by a factor of 10. In
contrast, simple competitive interactions (C) are characterized by mutu-
ally exclusive binding of the two ligands for the same site and, thus, allow
for a theoretically limitless dextral shift of orthosteric ligand occupancy.
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duced by the agonists is the same, deviations from this
behavior suggest that the tenet is not valid in this sys-
tem.
Another observation not consistent with the idea that
agonists simply enrich the spontaneously formed recep-
tor active state is the phenomenom of “protean ago-
nism”. This behavior has been described in theoretical
terms as the formation, by an agonist, of a receptor
active state that is less efficacious than the spontane-
ously formed constitutive one (Kenakin, 1995c, 1997b).
It was named for the Greek god Proteus who could
change shape at will. The hallmark of protean agonists
is the production of positive agonist response in noncon-
stitutively active systems and inverse agonism in con-
stitutively active ones. Such a pattern of response can be
used as presumptive evidence that the agonist produces
a receptor active state that is different (i.e., of lower
efficacy) than the spontaneously formed active state, i.e.,
ligand selective agonism. Under these circumstances,
protean agonism can be considered a looking glass into
receptor states.
There are theoretical conditions under which protean
agonism could occur. For example, in the CTC, a ligand
could promote the R* form of the receptor by having  
1 but then produce a liganded form of the receptor active
state of lower affinity than the unliganded form ( 	 1);
the result would be a reversal of the positive to a nega-
tive agonism under conditions of constitutive activity.
Importantly, there are also experimental examples of
protean agonism. The -adrenoceptor ligand dichloroiso-
proterenol has been shown to produce positive partial
agonism in Sf9 cells transfected with 2-adrenoceptors.
When membranes were prepared from these same cells,
the system demonstrated constitutive activity (due to
removal of cellular GTP) and dichloroisoproterenol then
became an inverse agonist. The same behavior was ob-
served for the ligands labetolol and pindolol (Chidiac et
al., 1994, 1996).
The kinetics of cyclic AMP formation have been used
to detect agonist-selective receptor states. Thus, in the
presence of limiting GTP concentrations, such kinetics
indicate a differential rate of heterotrimer dissociation
of G protein subunits with different -adrenoceptor ago-
nists (Krumins and Barber, 1997). Similarly, differences
in the ability of -adrenoceptor agonists to hydrolyze
inosine versus guanosine triphosphate suggest the for-
mation of ligand-specific receptor active states as well
(Seifert et al., 1999).
Mutation studies also suggest that ligands stabilize
different tertiary conformations of receptors. For exam-
ple, mutations of dopamine D2 receptors produce ago-
nist-specific abolition of G protein activation (Wiens et
al., 1998). Desensitization of receptors by some agonists
also suggests differential receptor active state forma-
tion. Whereas it would be expected that the ability of
agonists to induce desensitization would parallel their
ability to produce response (i.e., intrinsic efficacy), stud-
ies on -opioid receptors have indicated a disproportion-
ate desensitizing and receptor phosphorylating property
of methadone and L--acetyl methadone, thereby, sug-
gesting different receptor conformational changes with
these ligands (Yu et al., 1997). Differential desensitiza-
tion also has been demonstrated for methadone and
buprenorphine on -opioid receptors (Blake et al., 1997).
Studies with purified -adrenoceptor covalently la-
beled with cysteines with an environmentally sensitive
fluorophore 4[(iodoacetoxy)ethylemethylamino]-7-nitro-
2,1,3-benzoxadiazole allowed observation of changes in
protein conformation with ligand binding (Gether et al.,
1995). A statistical analysis of these data indicates seri-
ous deviation from a simple two-state model of receptor
activation suggesting that different ligands produce
uniquely different protein conformations (Onaran et al.,
2000).
The major window of detection of allosteric effects his-
torically has been receptor-mediated physiological re-
sponse. Thus, ligands have been detected as allosteric mod-
ulators or enhancers on the basis of effects resulting in
changes in tracer ligand affinity and/or tracer ligand-
induced response. However, different receptor conforma-
tions are involved in receptor-mediated effects other than
cellular signaling (Kenakin, 2002). Thus, conformations
resulting in changes in receptor phosphorylation and/or
receptor internalization also can be relevant to the thera-
peutic effect of allosteric ligands. For example, studies on
receptor internalization suggest ligand-specific receptor
conformations. Thus, the cholecystokinin receptor antago-
nist D-Tyr-Gly-[(Nle 28,31,D-Trp30)cholecystokinin-26–32]-
phenethyl ester is an antagonist on the receptor producing
blockade of responses to cholecystokinin but produces pro-
found acceleration of receptor internalization (Roettger et
al., 1997). This indicates the formation of a unique confor-
mation that does not signal to G proteins but is more
amenable to receptor phosphorylation and subsequent in-
ternalization. Similarly, whereas enkephalins and mor-
phine both stimulate - and -opioid receptors, enkepha-
lins induce rapid receptor internalization while morphine
does not (Keith et al., 1996).
2. Ligand-Specific Receptor Conformations. Although
the preceding discussion of specific receptor conformations
focused on the receptor-G protein interaction, it is evident
that the entire surface of a GPCR may be viewed as a
potential binding site, and any ligand binding to either the
orthosteric or allosteric site(s) on a GPCR has the potential
to alter receptor conformation such that the affinity and/or
intrinsic efficacy of a ligand binding to the other site(s) on
the GPCR will also change. This scheme is also compatible
with the potential for multiple ligand-specific receptor con-
formations to be engendered depending on the binding site
and extent of conformational change induced in the recep-
tor protein. Thus, ligands that would be classed as alloste-
ric modulators with respect to their effects on the endoge-
nous orthosteric agonist for the receptor of interest should
be placed in the same realm as other modifiers of receptor
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properties, such as agonists, inverse agonists, and G pro-
teins. At the molecular level, therefore, the classic TCM of
allosteric interactions and its variants (Fig. 2) are all sub-
sets of a more general, extended, model of receptor activity.
To visualize such a model, one can begin with a general
picture of a receptor protein that contains separate binding
sites for an orthosteric ligand, an allosteric modulator, and
a G protein. Thermodynamic considerations imply that the
occupancy of any one of the binding sites on this receptor
can alter its conformation such that the occupancy of any of
the other sites on the protein is also altered. This cross-
reciprocity can be quantified in terms of separate cooper-
ativity factors for the interaction between orthosteric and
allosteric sites, orthosteric and G protein sites, and alloste-
ric and G protein sites. Because efficacy at GPCRs is in-
variably related to the ability of the receptor to interact
with its cognate G protein(s), then efficacy at the molecular
level can be impacted not only by the interaction between
orthosteric ligand and G protein or orthosteric ligand and
allosteric modulator (e.g., Section IIB), but also by the
interaction of the allosteric modulator and the G protein.
For instance, Fig. 5A shows the effects of the allosteric
modulator alcuronium on PI hydrolysis in CHO cells trans-
fected with the human M1 muscarinic acetylcholine recep-
tor (Jakubı´k et al., 1996). Even in the absence of the mus-
carinic agonist carbachol, alcuronium was able to elicit a
significant stimulatory effect on PI hydrolysis that was
insensitive to antagonism of the orthosteric site by the
classical muscarinic antagonist quinuclidinyl benzilate.
The effect of alcuronium on PI hydrolysis was absent in
cells that did not express the M1 muscarinic receptor.
Thus, it can be concluded that alcuronium was promoting
receptor-G protein coupling via an action at the allosteric
site on M1 receptors. In a similar manner, the allosteric
modulator gallamine was also found to activate the M1,
M2, and M4 muscarinic receptors in the absence of any
other ligand (Jakubı´k et al., 1996), although it inhibits the
binding of the endogenous muscarinic agonist acetylcho-
line at the same receptors (Lazareno and Birdsall, 1995).
This latter finding is a striking example of ligand-specific
receptor conformations, whereby gallamine (and alcuro-
nium) can promote conformations that are positively coop-
erative for G protein coupling but negatively cooperative
for agonist binding.
Allosteric ligand-mediated receptor-G protein interac-
tions are not restricted to the muscarinic acetylcholine
receptors. Figure 5B shows the effect of the allosteric mod-
ulator PD 81,723 on the saturation binding properties of
the agonist [3H]N6-cyclohexyladenosine ([3H]CHA) at the
adenosine A1 receptor. In the absence of modulator, the
radiolabeled agonist could only recognize approximately
one-ninth of the total receptor population, as defined by the
binding of the radiolabeled antagonist, 8-[dipropyl-2,3-
3H(N)]cyclopentyl-1,3-dipropylxanthine, [3H]CHA (Kol-
lias-Baker et al., 1997). This finding indicated that the
agonist [3H]CHA was selectively labeling only high-
affinity receptor-G protein complexes, rather than the en-
tire receptor pool. Interestingly, the addition of PD 81,723
resulted in a significant enhancement in the total density
of binding sites recognized by [3H]CHA with no change in
the agonist KD value. This finding is inconsistent with a
direct allosteric effect of the modulator on agonist affinity,
but is in accord with a positive allosteric effect on recep-
tor-G protein coupling. In essence, it seemed as if PD
81,723 was able to “create” more binding sites by promot-
FIG 5. G protein-dependent effects of allosteric modulators. A, effects
of the orthosteric agonist, carbachol (E), and allosteric modulator, alcu-
ronium (), on phosphoinositol production in CHO cells transfected with
the human M1 muscarinic acetylcholine receptor. Data taken from
Jakubı´k et al. (1996). B, effect of the allosteric modulator, PD 81,723, on
the binding of the orthosteric agonist [3H]CHA to adenosine A1 recep-
tor-G protein complexes in CHO cells. Data taken from Kollias-Baker et
al. (1997).
G PROTEIN-COUPLED RECEPTOR ALLOSTERISM AND COMPLEXING 337
ing a greater proportion of high-affinity receptor-G protein
states for the radiolabeled agonist (Fig. 5B). This finding is
in agreement with previous studies using PD 81,723,
which showed that this particular modulator could en-
hance agonist binding to adenosine A1 receptors (Cohen et
al., 1994), decrease antagonist binding at these receptors
(Bruns and Fergus, 1990), and activate the receptors in its
own right (Bruns and Fergus, 1990).
It is evident, therefore, that allosteric modulators of
GPCRs may directly affect receptor function in the ab-
sence of orthosteric ligand and can, thus, be subdivided
into the following categories (Lutz and Kenakin, 1999).
(a) Allosteric enhancers: These ligands exert their ef-
fects by enhancing the affinity of the orthosteric ligand
for its site on the receptor. (b) Allosteric agonists: These
ligands exert their effects by promoting G protein cou-
pling independent of any effects on orthosteric agonist
binding. (c) Allosteric antagonists: These ligands can
exert their effects by one or a combination of mecha-
nisms; they can decrease the affinity of the receptor for
its orthosteric agonist and/or decrease the affinity of the
receptor for its G protein(s).
To be thermodynamically complete, any model of al-
losteric interactions between multiple ligands on the
same GPCR must, thus, take into account the ability of
the receptor to isomerize between multiple conforma-
tional states and to bind to G protein. At equilibrium,
each conformational state is characterized by its own set
of cooperativity factors. Even for the “simplest” case of
two receptor conformations (R for inactive and R* for
active) the resulting thermodynamic picture (Christo-
poulos et al., 1998) can become quite complicated; the
model is shown in Fig. 6. Nevertheless, this quaternary
complex model (QCM) of receptor allosterism reflects the
fact that allosteric modulators of GPCRs possess a rich
repertoire of behaviors that can extend beyond simple
changes on orthosteric ligand binding affinities. In ad-
dition to the possible ternary complexes comprising the
receptor, G protein, and either orthosteric or allosteric
ligand, the model also allows for the quaternary com-
plexes of orthosteric ligand, allosteric ligand, G protein,
and receptor in both active (AR*BG) an inactive states
(ARBG). Table 3 defines the constants and cooperativity
factors that describe the model, whereas Table 4 lists the
equations describing occupancy, potency, and response
parameters of an orthosteric ligand based on the model.
Table 5 shows the equations for KApp, response and EC50
from the QCM under the special conditions of [B]  0 or
[G]  0, where it can be seen that the model then
becomes formally identical with the CTC model of Weiss
et al. (1996a) or the allosteric two-state model of Hall
(2000), respectively. Thus, both latter models are sub-
sets of the quaternary complex model of allosterism at
GPCRs.
Although a detailed examination of the properties of
the QCM are beyond the scope of this review, one im-
portant aspect of the model is the ability to incorporate
allosteric modulator effects on receptor-G protein cou-
pling. For example, simulations based on the model (not
shown) reveal that an increase in the cooperativity fac-
tor , which governs G protein binding to the receptor
occupied by allosteric ligand, can result in an enhance-
ment of maximal orthosteric ligand binding capacity
(defined as total G protein-coupled receptors bound to
[A]) with no effect on apparent orthosteric ligand affin-
ity. This is exactly what has been observed experimen-
tally with the effects of PD 81,723 on adenosine A1
receptors (e.g., Fig. 5B) and cannot be accommodated
within the other allosteric receptor models described
above.
III. Detecting Allosteric Interactions
Allosteric interactions can be quite complex and there
are a number of pharmacological approaches that are
best used in tandem to successfully detect and quantify
such interactions at GPCRs. Allosteric phenomena can
be detected using radioligand binding assays and func-
tional tissue or cellular assays. Because many allosteric
effects are often subtle and characterized by different
degrees of cooperativity, screening assays will need to be
optimized for detecting these particular effects, and this
may entail using different conditions than would nor-
mally be used for screening orthosteric ligands.
A. Assays of Radioligand Binding
1. Equilibrium Binding Assays. Radioligand binding
assays often provide the most direct means for visualiz-
ing allosteric behavior. For example, Fig. 7A shows the
effects of the negative allosteric modulator, oleamide, on
the saturation binding properties of [3H] 5-HT at the
5-HT7 receptor expressed in HeLa cells, whereas Fig. 7B
shows the effect of the modulator gallamine on the sat-
uration binding of [3H]N-methylscopolamine at the M2
muscarinic receptor expressed in CHO cells. Although in
each instance the modulator is able to shift the radioli-
gand binding curves to the right, the allosteric nature of
the interaction is revealed as progressively higher con-
centrations of antagonist fail to cause significant dextral
displacements of the radioligand saturation curve.
These observations are in direct contrast to what would
be expected for a simple competitive interaction, where,
theoretically, there would be no limit to the dextral
displacement of the radioligand curve attainable in the
presence of increasing antagonist concentrations. A com-
mon graphical method for assessing the relationship
between radioligand saturation binding and antagonist
concentration involves the determination of the affinity
shift, that is, the ratio of radioligand affinity in the
presence (KApp) to that obtained in the absence (KA) of
each concentration of antagonist. A plot of log (affinity
shift  1) versus log [antagonist] should yield a straight
line with a slope of 1 for a competitive interaction, but a
curvilinear plot for an allosteric interaction. Such curves
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are evident in Fig. 7, C and D, which shows the affinity
shift plots for the interaction between oleamide and
[3H]5-HT or gallamine and [3H]N-methylscopolamine,
respectively.
2. Inhibition Binding Assays. Radioligand inhibi-
tion, or competition, binding assays are more commonly
used for the routine screening of novel chemical entities
than saturation binding assays, so it is quite likely that
the first detection of an allosteric modulator may occur
during this type of experiment. Of course, in the latter
instance, the interaction cannot be called competitive;
but for allosteric modulators with high degrees of nega-
tive cooperativity, the interaction may be mistaken as
competitive if low degrees of radioligand occupancy are
investigated. Because of this potential pitfall in inter-
preting inhibition binding experiments, it is useful to
explore the meaning of the standard observed parame-
ters in binding curves in terms of the simple allosteric
FIG 6. The quaternary complex model of allosteric interactions at GPCRs; a thermodynamically complete, extended model taking into account the
concomitant binding of orthosteric ligand, A, allosteric ligand, B, and G protein, G, on a receptor that can exist in two conformational states (R and
R). The model parameters are defined in Table 3.
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model outlined above (section IIB). Thus, an inverse
sigmoidal curve is predicted for an allosteric inhibition
of a given amount of bound radioligand much like what
is observed for a competitive antagonist. Considering
only specifically bound radioligand, the signal (
A) from
a radioligand [A], in the presence of a given concentra-
tion of allosteric antagonist [B], is given by eq. 5.
Whereas a competitive ligand will decrease the bound
ligand down to nonspecific binding levels, the maximal
inhibition produced by an allosteric antagonist will de-
pend upon the magnitude of the cooperativity factor, .
The maximal scale of inhibition of specific radioligand
binding is equal to
fractional maximal inhibition 
A KA
A
KA

(7)
It can be seen from this expression that the maximum
degree of antagonism of any given bound concentration of
radioligand A is a function of . This is because the inhi-
bition of a radioligand by either an allosteric ligand or a
competitive (i.e., orthosteric) ligand follows the receptor
occupancy of a single concentration of radioligand as the
saturation binding curve to that ligand is shifted to the
right by the nonradioactive ligand. This is shown in Fig.
8A, where the saturation curve to a radioligand is shifted
to the right by a high concentration of allosteric ligand with
 0.2. This results in a maximal shift to the right of 5-fold
by the allosteric ligand. If receptor occupancy is viewed at
a fixed radioligand concentration of approximately 1.5 
KA then the inhibition curve shown in the right panel of
Fig. 8A is observed. It can be seen that the strength of the
allosteric blockade (magnitude of ), thus, determines the
amount of maximal inhibition of the binding curve (see eq.
7.
The expected behavior of allosteric antagonists in inhi-
bition binding assays outlined in the preceding paragraph
gives rise to two important considerations. The first is that
a curve where the radioactivity is not inhibited completely
to nonspecific binding levels may denote an allosteric, as
opposed to a competitive, antagonism. Such an effect may
reflect the inability of the antagonist to produce large
enough shifts to the right of the saturation curve to bring
the signal completely to nonspecific binding levels. For
example, the small molecule antagonist of CCR3 chemo-
kine receptors UCB35625 is a full antagonist of chemo-
kine-induced chemotaxis but produces only a 15% maxmi-
mal displacement of radioactive chemokine binding
(Sabroe et al., 2000); this antagonist may be acting through
an allosteric mechanism. The second consideration is that
the maximal inhibition of specific radioligand binding at-
tainable by an allosteric antagonist will depend on the
concentration of radioligand. Thus, it can be seen that if a
radioligand concentration was chosen to be 0.01  KA,
then the antagonist shown in Fig. 8A would have taken the
binding to near nonspecific binding levels. Also, if the neg-
ative cooperativity is high, for example  is less than 0.1,
then the dependence of the maximal displacement window
on  becomes moot because the shift produced by the
allosteric antagonist would bring the binding down to non-
specific binding levels as well (see Fig. 8B). Hence, whereas
a maximal displacement above nonspecific binding levels
can denote allosteric antagonism, a complete displacement
to nonspecific binding levels does not necessarily implicate
competitive antagonism and preclude allosteric blockade.
Another potential method to detect allosteric, as opposed
to competitive, antagonism in radioligand binding studies
is to examine the relationship between the amount of ra-
dioligand present in the assay (denoted [A*]) and the
amount of antagonist required to reduce the specific bind-
ing produced by that radioligand to 50% of B0. For com-
petitive antagonists, this can be calculated from the Gad-
dum (1936) equation for competitive antagonism. Thus,
the receptor occupancy for a radioligand A* in the presence
of a competitive antagonist [B] is given by

A 
A*
KA
A*
KA
 1  BKB
(8)
where KA and KB are the equilibrium dissociation con-
stants of the radioligand and competitive antagonist,
respectively. From this equation, the concentration of
antagonist required to reduce a defined level of specific
radioligand binding to 50% B0 can be calculated as
B/KB  A*/KA  1 (9)
According to this relationship, therefore, the concentra-
tion of antagonist (expressed as a multiple of the KB) is
linearly related to the concentration of radioligand
present in the assay. This relationship, as defined for
enzymes, is commonly referred to as the Cheng-Prusoff
TABLE 3
Parameters defining the quaternary complex model of allosteric
interaction at GPCRs (Fig. 6)
Parameter Meaning
L Receptor isomerization constant
Ka Equilibrium association constant for orthosteric
ligand [A]
Kb Equilibrium association constant for allosteric
modulator [B]
Kg Equilibrium association constant for G protein [G]
 Activation cooperativity of [A] for the unliganded
receptor
 Activation cooperativity of [G] for the unliganded
receptor
 Binding cooperativity between [A] and [G]
 Activation cooperativity between [A] and [G]
 Binding cooperativity between [B] and [G]
 Activation cooperativity of [B] for the unliganded
receptor
 Activation cooperativity between [B] and [G]
 Binding cooperativity between [A] and [B]
	 Activation cooperativity between [A] and [B]
 Binding cooperativity between [A], [B], and [G]
 Activation cooperativity between [A], [B], and [G]
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(1973) relationship. A corresponding relationship for al-
losteric ligands can be also be derived
IC50  KB A KAA KA (10)
where IC50 denotes the concentration of allosteric antag-
onist producing 50% inhibition of specific radioligand
binding. It can be seen from this equation that if the
concentration of radioligand is low (i.e., if [A] 		 KA),
then the IC50 will be approximately equal to the KB (see
also Ehlert, 1988). It can also be seen that this is not a
linear relationship but rather a hyperbolic one. Thus,
one way to potentially differentiate competitive and al-
losteric antagonism in radioligand binding assays is to
compare the IC50 for blockade as a function of radioli-
gand concentration. Figure 8C shows such a relationship
for a competitive antagonist (linear dotted line) and a
series of allosteric antagonists with  values ranging
from 0.1 to 0.003. It can be seen that the pronounced
curvature of the relationship for the allosteric ligands
differentiates them from the competitive ligand.
The variability of the extent and the direction of allo-
steric modulation of radioligand binding can be practi-
cally demonstrated by the effects of two different allo-
steric modulators of M2 muscarinic acetylcholine
receptors on the same radioligand in the same mem-
brane preparation. Figure 9A shows the interaction be-
tween the muscarinic receptor antagonist [3H]N-meth-
ylscopolamine and the allosteric modulator gallamine,
which is characterized by negative cooperativity. It can
be seen that the use of a sub-KA concentration of radio-
ligand (which is quite common for these types of screen-
ing assays) results in an apparently complete inhibition
of specific radioligand binding. Increasing the concentra-
tion of the radioligand to 10 times its KA, however,
unmasks the limited ability of the negative allosteric
modulator to inhibit specific binding. In contrast, the
interaction between the same radioligand and the mod-
ulator, alcuronium, at the same receptor, is character-
ized by a marked positive cooperativity, clearly deviat-
ing from the predictions of simple competition (Fig. 9B).
Findings such as these highlight another important as-
pect of allosteric interactions, that is, they are unique for
each and every pair of interacting ligands involved. A
positive allosteric modulator of one particular orthos-
teric ligand is not necessarily a positive modulator of
another orthosteric ligand. Table 6 demonstrates this
with examples of the interaction between alcuronium
and a variety of orthosteric ligands at the M2 muscarinic
acetylcholine receptor.
The preceding discussion suggests important practical
considerations when screening for allosteric ligands. For
instance, assays can generally use low concentrations of
radioligand (	KA) in the first instance, but these may
then need to be supplemented with assays using a high
radioligand concentration to demonstrate the limiting
effects of cooperative interactions on the pattern of the
resulting binding curve. Second, because the allosteric
interaction is unique for each drug pair, it is logical that
screening programs for allosteric ligands should include,
at the very least, the endogenous hormone or neuro-
transmitter for the receptor of interest as part of the
assay. Yet another important factor in radioligand bind-
ing experiments is the actual choice of radioligand. Ag-
onist radioligands rely on the ability of the receptor to
couple to G proteins and would be most useful in detect-
ing allosteric modulators that are able to modify recep-
tor-G protein coupling, whereas radiolabeled antago-
nists may not. In general, the design of radioligand
binding assays to detect allosteric modulators should,
TABLE 5
Meaning of observed affinity (KApp), (fractional) response, and EC50 in the quaternary complex model under different limiting conditions
[B]  0 [G]  0a
KApp KA1  L  GKG 1  L
1  L  G
KG
1  L
KA1  L  BKB 1  L 
1  L  B
KB
1  	L
Response LG
KG
1  A
KA

1  L 
G
KG
1  L
A
KA
1  L  G
KG
1  L
L1  A
KA

B
KB
1  	A
KA

1  L 
B
KB
1  L
A
KA
1  L  B
KB
1  	L
EC50
EC50 
KA1  L  GKG 1  L
1  L 
G
KG
1  L
EC50 
KA1  L  BKB 1  L
1  L 
B
KB
1  	L
a In the absence of [G], the expression for response is more accurately defined as the stimulus and is equal to ([R*] 
 [AR*] 
 [BR*] 
 [AR*B])/[R]T.
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where possible, use the endogenous orthosteric ligand
for the receptor of interest as the radiolabel. If this is not
possible, then the radioligand used may still detect an
allosteric interaction, but the experimenter should re-
main aware that the magnitude and direction of that
interaction can be quite different from the situation with
the endogenous ligand probe.
Sometimes, radioligand binding assays may reveal
unusual behavior that may not seem compatible with
the simple allosteric TCM. Figure 10A shows the inter-
action between methylisobutylamiloride (MIA) and
[3H]spiperone at the dopamine D2 receptor, which is
characterized by a very steep inhibition curve (Hill
slope  2), and Fig. 10B shows the interaction between
PD 81,723 and the agonist [3H]CHA at the adenosine A1
receptor, which is characterized by a bell-shaped curve.
Although each of these interactions involves allosteric
mechanisms, it has been suggested that MIA and PD
81,723 can interact with both orthosteric and allosteric
sites at the D2 and A1 receptors, respectively (Bruns and
Fergus, 1990; Hoare and Strange, 1996). This leads to an
additional level of complexity in the observed binding
profiles. Specifically, if a modulator is able to compete
with the radioligand at the orthosteric site and modulate
the radioligand’s binding (and its own) through an ad-
ditional allosteric mechanism, then the curves illus-
trated in Fig. 10, A and B, may be observed. The rele-
vant model in this instance is shown in Scheme 2, where
the parameters are as defined previously except that
subscript 1 refers to binding of ligand B to the orthos-
FIG 7. Allosteric modulation by oleamide (A and C) of the binding of [3H]5-HT in HeLa cell membranes transiently transfected with the 5-HT7
receptor or gallamine (B and D) of the binding of [3H]NMS in cell membranes stably transfected with the human M2 muscarinic acetylcholine receptor.
A, radioligand saturation binding curves obtained in presence of the following concentrations of oleamide: 0 (E), 0.1 nM (‚), 10 nM (F), 30 nM (Œ), 100
nM (f), 300 nM (), and 1 M (). B, effect of oleamide on the ratio of [3H]5-HT KD values (“affinity-shift”) determined in the presence or absence
of the modulator. The dashed line shows the predicted behavior of a competitive antagonist. Data taken from Hedlund et al. (1999). C, radioligand
saturation binding curves obtained in presence of the following concentrations of gallamine: 0 (F), 1 M (E), 3 M (), 10 M (), and 100 M (‚).
D, affinity-shift for the interaction between [3H]NMS and gallamine. Data taken from Christopoulos (2000b).
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teric site, subscript 2 refers to binding of B to the allo-
steric site, and the cooperativity factor, , denotes the
allosteric interaction between the two molecules of B on
the receptor. From this model, the following equation
can be derived describing the fractional receptor occu-
pancy by A at equilibrium.

A 
A
KA
1  B/KB2
A
KA
1  B/KB2 1  B/KB1
 B/KB21  B/KB1
(11)
where KA, KB1, and KB2 denote equilibrium dissociation
constants. eq. 11 was used to simulate the binding
curves shown in Fig. 10, C and D. In Fig. 10C, the
interaction between the two molecules of B is positively
cooperative (  1), whereas the interaction between B
and A is negatively cooperative ( 	 1). This yields a
very steep inhibition curve (Hill slope of approximately
2), as was observed experimentally for the interaction
between MIA and [3H]spiperone at the D2 receptor. In
Fig. 10D, the interaction between A and B is positively
cooperative ( 1), whereas the interaction between the
two molecules of B is neutrally cooperative (  1),
yielding the observed bell-shaped curve.
3. Nonequilibrium (Kinetic) Studies. The study of
allosteric modulator effects on radioligand kinetic bind-
ing properties probably represents the most sensitive
direct measurement of allosteric interactions at GPCRs.
The rates of association and dissociation of a ligand from
its binding site (be it orthosteric or allosteric) on a re-
ceptor are exponential processes. Importantly, the ac-
tual rate constants that govern the ligand association
(kon) and dissociation (koff) can be determined experi-
mentally from kinetic experiments that measure radio-
ligand binding as a function of time, and are very sen-
sitive indicators of the interaction of the ligand with a
particular conformation of receptor. Hence, a change in
receptor conformation induced by an allosteric agent
would be expected to result in an alteration of orthos-
teric ligand association and/or dissociation characteris-
tics. It is this alteration in orthosteric ligand kinetics
that underlies the effects of allosteric modulators on
orthosteric ligand affinity at equilibrium.
From the simple TCM, the association constant, Ka,
can be re-defined according to its respective kinetic rate
constants. That is, Ka  konA/koffA, where konA equals the
association rate constant and koffA equals the dissocia-
tion rate constant of ligand A. In the simplest case (and,
thus far, the most commonly observed experimental sit-
FIG 8. Inhibition of radioligand binding by allosteric antagonists. A, Saturation binding curve for a radioligand shifted to the right by a maximally
effective concentration of allosteric antagonist with   0.2. The curve to the left of the panel shows the displacement of a defined concentration of
radioligand by a range of concentrations of allosteric antagonist. Note how the displacement does not reduce the bound counts to nonspecific binding
levels. B, same as A but for a more powerful allosteric antagonist (  0.01). In this case, the displacement counts are reduced to nonspecific binding
levels. C, the increase in the IC50 for antagonism (as a ratio of the KB) as a function of the amount of radioligand in the assay (as a ratio of KA). A linear
relationship is predicted for a competitive ligand. For allosteric ligands, hyperbolic curves are generated.
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uation), the kinetics of the modulator are more rapid
than those of the orthosteric ligand. Under these condi-
tions, the rate of dissociation of an orthosteric ligand in
the presence of an allosteric modulator may be derived
as follows (Lazareno and Birdsall, 1995; Christopoulos,
2000b)

At  
A  ekoffobst (12)
where
koffobs 
BkoffAB/KB  koffA
1  B/KB
(13)
In these two equations, 
At denotes the receptor occu-
pancy by [A] at time t, 
A denotes the receptor occupancy
by [A] at equilibrium, koffobs denotes the experimentally
observed dissociation rate constant for [A], and koffAB
denotes the dissociation rate constant for [A] from the
ternary complex [ARB]. The remaining parameters are
as defined previously. The association of an orthosteric
ligand under similar conditions is derived as

At  
A  1  ekonobst (14)
where
konobs  koffobs1  AKApp (15)
The parameter, konobs, denotes the apparent association
rate constant of orthosteric ligand in the presence of
allosteric modulator. KApp is defined in eq. 6.
Allosteric modulators may increase or decrease the
association and/or dissociation characteristics of the or-
thosteric ligand at its binding site on the receptor. Pos-
itive allosteric modulation can, thus, be manifested
through an overall enhancement of orthosteric ligand
association rate and/or a reduction in dissociation rate.
To date, however, an enhancement of orthosteric ligand
association rate has not been conclusively demonstrated
for any allosteric modulators of GPCRs, although a re-
cent study by Molderings et al. (2000) has suggested
that agmatine is able to enhance the association rate
and retard the dissociation rate of [3H]clonidine at the
2-adrenoceptor through an allosteric mechanism, thus,
enhancing radioligand affinity at equilibrium. For neg-
ative allosteric modulators, their equilibrium effects on
orthosteric ligand affinity can generally be mediated via
slowing orthosteric ligand association and/or enhancing
dissociation. Unfortunately, the former mechanism is
experimentally difficult to distinguish from simple com-
petitive inhibition because competition will also lead to
an apparent reduction in the observed orthosteric ligand
association rate. In contrast, dissociation kinetic exper-
iments theoretically monitor only the disintegration
characteristics of a preformed orthosteric ligand-recep-
tor complex, and any changes in the observed dissocia-
tion rate are much more unambiguously attributed to
FIG 9. Effect of the allosteric modulators gallamine and alcuronium
on the binding of the orthosteric antagonist, [3H]N-methylscopolamine,
at M2 muscarinic acetylcholine receptors in guinea pig atrial membranes.
A, negative cooperativity between gallamine and two different concentra-
tions of the radioligand: 0.1 nM (E; 0.5  KA) and 2 nM (F; 10  KA). B,
positive cooperativity between alcuronium and 0.1 nM radioligand. Also
shown on the figure are the best estimates based on fitting the data to the
allosteric model (eq. 5). Data taken from Christopoulos (2000a).
TABLE 6
Cooperativity factors for the allosteric modulator, alcuronium, at the M2
muscarinic acetylcholine receptor
Orthosteric Ligand 1/
Agonistsa
Arecoline 1.7
Acetylcholine 10
Bethanecol 10
Carbachol 9.5
Furmethide 8.4
Methylfurmethide 7.3
Antagonists
Atropineb 0.26
Methyl-N-piperidinyl benzilateb 0.54
Methyl-N-quinuclidinyl benzilateb 63
Methyl-N-scopolaminec 0.24
a Data from Jakubı´k et al., 1997.
b Data from Hejnova et al., 1995.
c Data from Proska and Tucek, 1994.
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allosteric effects. These latter types of experiments,
therefore, represent the most common type of radioli-
gand kinetic assay used to detect and quantify alloster-
ism at GPCRs.
Figure 11A shows the effects of the allosteric modula-
tor 5-(N-ethyl-N-isopropyl)-amiloride (EPA) on the dis-
sociation of [3H]yohimbine from the human 2A-adreno-
ceptor. It can be seen that increasing the concentration
of EPA results in a progressive increase in the dissocia-
tion of the orthosteric radioligand as the occupancy of
the allosteric site by EPA becomes greater. This effect
explains the reduction in [3H]yohimbine affinity by EPA
observed in equilibrium binding assays. In contrast, the
allosteric modulator, PD 117,975 slows the dissociation
rate of the agonist [3H]CHA from adenosine A1 receptors
(Fig. 11B), thus, accounting for its positively cooperative
effects on agonist radioligand affinity at equilibrium. An
interesting situation can arise, however, with certain
allosteric modulators. Figure 12 illustrates the effects of
the modulator, tetra-W84, on the apparent association
and dissociation rates of the orthosteric antagonist
[3H]N-methylscopolamine from the cardiac M2 musca-
rinic acetylcholine receptor. It can be seen that the con-
centration-effect curves for the ability of the modulator
to slow both kinetic properties of the radioligand are
very close together. The consequence of this dual effect is
seen in the curve of the interaction between tetra-W84
and [3H]N-methylscopolamine determined separately in
an equilibrium binding assay (open circles). Under equi-
librium binding conditions, it seems that tetra-W84 has
no effect on binding. In fact, this is an example of a
neutrally cooperative interaction (  1). Its allosteric
nature is quite convincingly revealed in the radioligand
kinetic assays, whereas it can be missed in equilibrium
binding assays. Finally, it should also be noted that
allosteric modulation of orthosteric ligand equilibrium
affinity may be brought about by changes in both asso-
ciation and dissociation rates of the orthosteric ligand in
the same direction (e.g., slowing or enhancing), provided
that the magnitude of the change is not uniform for both
rate constants. For example, most negative allosteric
FIG 10. Mixed modes of allosteric/competitive interactions. A, inhibition of [3H]spiperone binding by MIA at dopamine D2 receptors in membranes
from Ltk59 cells. The dotted line corresponds to a curve fit based on the simple allosteric ternary complex model (eq. 5) or to a simple model of
competitive interaction. The solid line denotes the fit of the data to a model allowing for the allosteric modulator to recognize both orthosteric and
allosteric sites. Data taken from Hoare and Strange (1996). B, enhancement and inhibition of the binding of the agonist, [3H]N6-cyclohexyladenosine
([3H]CHA) by the modulator PD 81,723 at the A1 adenosine receptor in rat brain membranes. Data taken from Bruns and Fergus (1990). C, simulations
based on a model of concomitant orthosteric and allosteric binding by an allosteric modulator (eq. 11). The following parameters were used pKA  4.6,
pKB1  pKB2  4.7,   0.25,   27, and log[A]  5. D, simulations based on the same model, but with the following parameters pKA  9, pKB1 
pKB2  5,   7,   1, and log[A]  9.
SCHEME 2.
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modulators of muscarinic acetylcholine receptors are
known to retard the dissociation rate of orthosteric ra-
dioligands while still reducing equilibrium binding af-
finity (Ellis, 1997). This can most easily be reconciled in
a mechanism where orthosteric ligand association is also
slowed by the modulator to a greater extent than disso-
ciation.
The quite profound effects that allosteric modulators
can exert on orthosteric ligand kinetics can also lead to
pitfalls in data analysis and interpretation. The most
insidious effect is seen in binding experiments that are
ostensibly conducted under standard “equilibrium” con-
ditions but are, in fact, not at equilibrium due to the
marked effects of the modulator on orthosteric ligand
association and dissociation. This is most commonly ob-
served with positive and neutrally cooperative ligands
because their kinetic effects on the approach of the sys-
tem to equilibrium occur over most concentrations of
modulator that are tested, thus, increasing the likeli-
hood of equilibrium not being achieved over the time
course of a typical experiment. The consequences of this
kinetic artifact can be modeled using eq. 14 and are
shown in Fig. 13. Even after 64 h, a positive allosteric
modulator that is able to completely inhibit the dissoci-
ation of an orthosteric ligand from the ARB complex
(koffAB  0) yields a bell-shaped binding curve. The ef-
fects of high concentrations of the modulator on the
kinetics of the orthosteric ligand are so marked that
equilibrium has not been achieved in the presence of the
high modulator concentrations. Only after 2048 h (ap-
proximately 85 days) is equilibrium achieved. Experi-
mentally, the easiest way of circumventing this problem
is to prelabel the receptors with orthosteric radioligand
before exposure to the allosteric agent (see Lazareno and
FIG 11. Effects of allosteric modulators on orthosteric ligand dissoci-
ation kinetics. A, enhancement of the dissociation rate of [3H]yohimbine
from the human 2A receptor expressed in CHO cell membranes by the
modulator EPA. Data taken from Leppik et al. (1998). B, slowing of the
dissociation rate of [3H]CHA from the adenosine A1 receptor in rat brain
membranes by the modulator PD 117,975. Data taken from Bruns and
Fergus (1990).
FIG 12. Neutral cooperativity between [3H]N-methylscopolamine and
the modulator, Tetra-W84 at the M2 muscarinic acetylcholine receptor.
Increasing concentrations of modulator are able to decrease the rate of
radioligand association and dissociation, thus, revealing the allosteric
nature of the interaction (solid symbols). However, because the kinetics of
the radioligand are influenced over similar concentration ranges and to
similar extents, equilibrium binding studies show minimal effects on
levels of radioligand binding (open circles). Data taken from Kostenis and
Mohr (1996).
FIG 13. Allosteric modulation under nonequilibrium conditions. Or-
thosteric radioligand binding was simulated for a positive allosteric mod-
ulator (  10) using eqs. 12 through 15 and the following parameters:
pKA  pKB  7, koffA  0.5 min
1, koffAB  0 min
1, and log[A]  7. The
curves represent the concentration-occupancy relationship for the inter-
action at the different times (hours) shown in the figure. It is evident that
allosteric modulators may slow the kinetics of the system to such an
extent that equilibrium is unachievable during the time course of the
experiment, thus, yielding complex binding curves.
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Birdsall, 1995; Christopoulos, 2000b). Alternatively, the
use of nonequilibrium kinetic assays to directly quantify
the interaction may be preferred (Lazareno and Birdsall,
1995). Parenthetically, this kinetic effect is reminiscent
of the binding profile that has been seen in equilibrium
binding assays in some receptor systems (e.g., Fig. 10B).
Although that binding profile may be due to mixed allo-
steric/competitive modes of interaction, the investigator
must first rule out any kinetic artifacts of the allosteric
modulator on the approach of the orthosteric radioligand
to equilibrium.
B. Assays of Receptor Function
Although radioligand binding assays provide the most
direct means for visualizing and quantifying allosteric in-
teractions at GPCRs, functional assays of receptor activity
can also be used. In fact, the earliest demonstrations of
receptor allosterism relied on these types of assays. Ac-
cording to the simple TCM (Fig. 2), an allosteric modulator
that affects orthosteric ligand affinity but not efficacy will
displace the concentration-response curves of an orthos-
teric agonist in a parallel fashion with no change in basal
response, maximal tissue response, or curve shape and
slope. In the case of positive cooperativity, the ascription of
an allosteric mechanism to the experimental data would be
relatively straightforward, because the agonist curves
would be displaced to the left of the control agonist curve.
However, as is the case for radioligand binding assays,
negative allosteric modulation may be misinterpreted as
competitive antagonism, particularly for modulators with
high degrees of negative cooperativity. An important key to
the successful detection and quantification of negative al-
losteric modulation is to investigate the effects of as large
a range of antagonist concentrations as is practicable. The
classic approach to quantifying antagonism using this type
of protocol is based on Schild analysis (Arunlakshana and
Schild, 1959) and its variants.
1. Schild Analysis. Competitive antagonism follows a
strict adherence to the model defined by Gaddum (1936,
1957) and quantified by Arunlakshana and Schild (1959).
Thus, the effect of a competitive antagonist on the conce-
tration-response curve to an agonist is strictly defined by
the term 1 
 [B]/KB, where [B] is the concentration of
antagonist and KB the equilibrium dissociation constant of
the receptor-antagonist complex. Under these circum-
stances, the dextral displacement produced (expressed as
“CR”, which is the equiactive concentration ratio of agonist
concentrations measured in the presence and absence of
antagonist) is related to [B] and KB by the Schild equation
(Arunlakshana and Schild, 1959).
logCR  1 logB log KB (16)
The slope and linearity of the Schild regression be-
come very useful criteria for the definition of competitive
antagonism. Deviations from linearity or from a line
with slope of unity can occur as a result of a number of
nonequilibrium situations including agonist uptake pro-
cesses, receptor heterogeneity, and temporal disequilib-
rium (Kenakin, 1982). However, one notable deviation
also can occur with allosteric antagonism. Specifically,
an allosteric antagonist can produce a Schild regression,
which, at some point along the concentration axis, devi-
ates from linearity or has a slope of less than unity. This
would occur because of the saturable nature of the an-
tagonism (i.e., the magnitude of ). Thus, allosteric an-
tagonists will shift the agonist concentration-response
curve to the right according to a limit defined by (1 

[B]/KB)/(1 
 [B]/KB). These relationships become very
apparent when plotted in the form of Schild regressions,
with the maximal concentration-ratio attainable being
determined by the cooperativity factor, . Figure 14A
shows the antagonism by gallamine of the negative ino-
tropic effects of acetylcholine at M2 muscarinic receptors
in the guinea pig electrically stimulated left atrium. It
can be seen that as the concentration of modulator is
increased, the dextral displacement of the acetylcholine
curves approaches a limit. The Schild regression of the
same data are shown in Fig. 14B, where the deviation
from a straight line is clearly evident. In fact, a linear
regression through the data points yields an unsatisfac-
tory fit with a slope factor of 0.65. The appropriate fit of
the allosteric model to the data can be obtained with the
following equation (Ehlert, 1988).
logCR  1 logB1  
B KB
 (17)
As shown in Fig. 14B, eq. 17 allows an estimate to be
obtained of the cooperativity factor and the dissociation
constant of the modulator for the allosteric site.
Another prediction of the allosteric model directly re-
lated to the dependence of allosterism on the choice of
orthosteric ligand (e.g., agonist) is the phenomenon of
agonist-specific degrees of antagonism. This trait is also
demonstrated by gallamine (Clark and Mitchelson,
1976; Kenakin and Boselli, 1989). Although gallamine
produces dextral displacement of muscarinic agonist
concentration-response curves in rat trachea, the result-
ing regressions are agonist-dependent (Fig. 14C), and
some deviate from a slope of unity (Kenakin and Boselli,
1989). Agonist-dependent Schild regressions can also be
obtained in systems with mixtures of receptors
(Kenakin, 1982, 1992), but in those instances, the pat-
tern is a set of parallel displaced Schild regressions with
differing intercepts (pA2 values). In contrast, allosteric
antagonism would show the pattern in Fig. 14C, namely,
little change in intercept with deviations occurring at
higher concentration ratios (as saturation of the alloste-
ric sites occurs).
2. Additivity of Concentration Ratios. As discussed
previously, competitive antagonism defines a formal re-
lationship between the concentration of the antagonist
and its expected effects on agonist concentration-re-
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sponse curves, i.e., a parallel dextral displacement with
no diminution of curve maxima, and a magnitude of
curve shift defined by the Schild equation. The addition
of a second antagonist to a mixture of agonist and an-
tagonist would simply produce re-equilibration of the
three molecules with their respective contributions to
receptor activity being defined by the ratio of their con-
centration and equilibrium dissociation constants (i.e.,
[B1]/KB1 
 [B2]/KB2 
 [B3]/KB3 . . . etc.). Thus, the mea-
sured effect of adding a second antagonist of known
receptor potency into a system can be used to detect
possible deviation from true competitivity by the two
antagonists in terms of additive concentration ratios
(Paton and Rang, 1965). Specifically, if two antagonists,
B and C, were combined and tested against an agonist,
then their combined concentration-ratio (CRBC) would
be given as follows for a competitive interaction.
CRBC  CRB  CRC  1 (18)
where CRB and CRC denote the concentration ratios
obtained for the agonist in the absence or presence of
each respective antagonist alone. In contrast, if the an-
tagonists were not mediating their inhibitory effects by
a simple competitive mechanism through the orthosteric
binding site, then CRBC would be a multiplicative,
rather than additive, function of CRB and CRC (Paton
and Rang, 1965). For the specific case of the allosteric
TCM, the actual expression for the interaction between
an agonist, a competitive antagonist (B) and an alloste-
ric modulator (C) is given as (Christopoulos and Mitch-
elson, 1994).
CRBC  CRC1  CRB  1C/KC  1C/KC  1  (19)
where  denotes the cooperativity factor for the inter-
action between the antagonist, B, and modulator, C. A
direct consequence of the dependence of allosteric mod-
ulation on the ligand occupying the orthosteric site is
that markedly greater-than-additive or less-than-addi-
tive combination concentration ratios may be observed,
clearly deviating from the additivity predicted by simple
competition. Figure 15A illustrates this with an example
of the interaction between the muscarinic agonist car-
bachol, the orthosteric antagonist N-methylscopol-
amine, and the allosteric modulator alcuronium. The
dashed line represents the expected shift of the carba-
chol curve in the presence of both N-methylscopolamine
and alcuronium if the interaction between all ligands
was competitive. This predicted shift was calculated
from the individual shifts produced by either N-methyl-
scoplamine or alcuronium alone. However, the actual
observed shift lies much farther to the right of the pre-
dicted shift, an example of supra-additive antagonism.
This finding is consistent with the known ability of al-
curonium to allosterically potentiate the binding of N-
methylscopolamine, while simultaneously reducing the
binding of carbachol, thus, enhancing the overall antag-
onism observed.
FIG 14. Schild analysis of allosteric interactions. A, effects of acetylcholine (ACh) on the electrically evoked contractions of the guinea pig left
atrium in the absence (f) or presence of the allosteric modulator gallamine at the following concentrations: 10 M (Œ), 30 M (), 100 M (), 300
M (), and 500 M (F). All experiments were conducted in the presence of the cholinesterase inhibitor, diisopropylfluorophosphate. B, Schild plot
of the data shown in A. The solid line (slope  1) denotes the behavior expected for a competitive antagonist, whereas the dashed line shows the best
fit linear regression (and associated slope factor) through the points. The curve through the points and associated parameter estimates represent the
fit of the allosteric model (eq. 17). Data taken from Christopoulos (2000a). C, agonist-dependence of functional allosterism. Schild regressions for
gallamine as an antagonist of muscarinic agonist responses in rat trachea. Data taken from Kenakin and Boselli (1989).
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Concentration-ratio analysis is not only restricted to
the combination of orthosteric antagonists with alloste-
ric modulators. The combination of two allosteric mod-
ulators against an agonist can also be studied using this
approach. This is particularly useful in demonstrating
whether two different allosteric modulators interact
with the same allosteric site on a GPCR. In this in-
stance, the appropriate equation is (Lanzafame et al.,
1997).
CRBC 
1 
CRB  1
  CRB

CRC  1
  CRC
1 
CRB  1
  CRB

CRC  1
  CRC
(20)
where B and C denote two different allosteric modula-
tors, and  and  denote their respective cooperativity
factors for interaction with the agonist. Figure 15B il-
lustrates the interaction between carbachol and the two
modulators, alcuronium and heptane 1,7-bis-(dimethyl-
3-pthalimidopropyl) ammonium bromide, at atrial mus-
carinic receptors. The excellent agreement between the
observed carbachol curve in the presence of both modu-
lators and the predicted curve based on eq. 20 is in
accordance with both modulators interacting with the
same allosteric site on the M2 muscarinic receptor.
3. Pharmacological Resultant Analysis. Although
the additivity-of-concentration-ratio approach described
above is obviously useful in detecting allosterism, a po-
tentially significant shortcoming of this procedure is the
required tacit assumption that neither antagonist has a
secondary property that modifies the system sensitivity.
A powerful tool to measure the additive effects of antag-
onists that does not have this handicap is pharmacolog-
ical “resultant analysis” (Black et al., 1986). This tech-
nique compares the effect of a “test” antagonist on the
observed antagonism produced by a “reference” antago-
nist. The strength of this method lies in the fact that the
test antagonist is added to the system from the very
start of the experiment (even present for the control
curve), and, thus, any secondary effects of this antago-
nist are negated by the fact that these effects are present
for all measurements of sensitivity of the system to the
reference antagonist and, thus, cancel. Several Schild
regressions for the reference antagonist are obtained in
the presence of different concentrations of the test an-
tagonist and then the displacements of these Schild
plots, along the reference antagonist concentration axis,
are used to construct resultant plots. These have strictly
defined properties for two competitive antagonists,
therefore, deviations from these requirements may indi-
cate allosterism in the actions of the test antagonist.
The response (E) to an agonist in the combined pres-
ence of a test antagonist [C] and reference antagonist [B]
is given by
E f
A
A KA1  BKB  CKC
(21)
where [A] refers to the concentration of agonist in the
absence of reference antagonist, [A] refers to the con-
centration of agonist in the presence of reference antag-
onist, [B] refers to the concentration of reference antag-
onist in the presence of test antagonist ([C]), and KA, KB,
and KC refer to the respective equilibrium dissociation
constants of the receptor and molecules A, B, and C. The
response in the absence of reference antagonist (denoted
as E) is given by eq. 21 with [C]  0. Comparison of
equiactive concentrations (E  E) with the reference
antagonist present and not present is given by
A
A  r  1 
B
KB1  CKC
(22)
A ratio, r, can be defined for equiactive agonist doses
in the absence of test antagonist by setting [C]  0 in eq.
22. Comparing equal levels of antagonism (in essence
measuring the dextral displacement of Schild regres-
sions along the test antagonist axis at a constant level of
antagonism) leads to the expression of equiactive (from
the point of view of equal levels of antagonism) concen-
trations of the reference antagonist in the absence ([B])
and presence ([B]) of test antagonist.
B
B  1 
C
KC
(23)
The logarithmic metameter of eq. 23 is
log 1 logC log KC (24)
FIG 15. Additivity of concentration-ratio analysis. A, M2 muscarinic
acetylcholine receptor-mediated effect of carbachol on the electrically
evoked contractions of the guinea pig left atrium in the absence (F) or
presence of the antagonist, 3 nM N-methylscopolamine, alone () or
combined with the allosteric modulator, 10 M alcuronium (). The
dashed line shows the expected location of the agonist curve in the
presence of both antagonists if all ligands were interacting in a compet-
itive manner at the orthosteric site, based on eq. 18. B, effect of carbachol
in the absence (F) or presence () of the combination of the two allosteric
modulators, 10 M alcuronium and 10 M heptane 1,7-bis-(dimethyl-3-
pthalimidopropyl) ammonium bromide. The dashed line shows the ex-
pected location of the agonist curve in the presence of both antagonists if
the inhibitors were interacting in a competitive manner at a common
allosteric site, based on eq. 20. Data taken from Lanzafame et al. (1997).
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Thus, a plot of log (  1) as a function of concentration
of test antagonist should be linear and have a slope of
unity with an intercept equal to the equilibrium disso-
ciation constant of the test antagonist. This latter pa-
rameter can be measured independently; thus, there are
three observable tests (slope, linearity, and intercept) for
competitivity in this procedure, including one that can
be independently verified, consistent with the known
allosteric nature of gallamine’s mechanism of action.
Although resultant analysis, as described above, is a
powerful technique for detecting allosterism, it is unable
to quantify the allosteric interaction because, in its orig-
inal form, it is not formulated based on an allosteric
model. However, the theoretical underpinnings of the
procedure can readily be modified to incorporate an al-
losteric model (Christopoulos and Mitchelson, 1997),
leading to the following variant of eq. 24.
log  1
C1  
KC  C
(25)
Thus, the methodology behind pharmacological result-
ant analysis allows for both the detection of allosteric
interactions between two antagonists in a functional
tissue assay and for the derivation of quantitative pa-
rameters describing the interaction.
C. Potential Pitfalls
Because allosteric interactions are noncompetitive in
nature, they can be manifested in a variety of ways and
are usually first detected when the researcher notes a
deviation of their experimental data from the expecta-
tions of simple (competitive) mass-action kinetics. How-
ever, similar findings may also be made due to other
experimental artifacts, such as inappropriate drug
equilibration times, drug solubility problems, or perhaps
too concentrated a receptor preparation (in binding as-
says). Thus, it is important first to rule out other reasons
for “anomalous” data before studies are initiated that
specifically aim to examine potential allosteric proper-
ties of ligands under investigation. Figure 16 illustrates
a flow-chart strategy for assessing potential allosteric
modulators for artifactual properties before attempting
quantification of allosterism. In addition, there are a
number of general considerations that pertain to all
types of radioligand binding assays that must first be
considered.
Due to the dependence of allosteric phenomena on the
nature of the ligand occupying the orthosteric site, ra-
dioligand binding assays can yield quite different results
even if the same modulator is studied at the same re-
ceptor. As discussed previously, factors such as radioli-
gand choice, concentration, and equilibration time can
have profound effects on the detection, or lack thereof, of
allosteric phenomena. Even the concentration of mem-
brane-bound receptors can have a significant impact on
the detection of allosterism in binding assays, particu-
larly when dissociation kinetic assays are used. In par-
ticular, some discussion is warranted about the most
significant kind of experimental artifact in kinetic as-
says that is related to receptor concentration, namely
the phenomenon of binding at the “collisional limit”.
When the density of receptors exceeds 5,000 to 10,000
sites per cell, the probability of a dissociated molecule of
ligand diffusing away into the bulk medium according to
simple bimolecular mass-action kinetics is significantly
decreased to the point that re-binding to adjacent recep-
FIG 16. Flow chart strategy for dealing with compounds identified as potential allosteric modulators. Adapted from Christopoulos (2000b).
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tors occurs. Under these circumstances, binding is con-
sidered to have reached the collisional limit (Abbott and
Nelsestuen, 1988; Kenakin, 1997c). As a consequence,
the apparent dissociation rate constant of a ligand that
is examined under conditions of collision-limited binding
will seem much smaller than if the dissociation were
monitored when receptor density is much lower. Most
important for the study of allosteric phenomena, colli-
sion-limited dissociation will seem different if dissocia-
tion is promoted by a large (100-fold) dilution of radi-
oligand-bound receptor preparation in buffer as opposed
to isotopic dilution, that is, the addition of a large excess
of unlabeled orthosteric competitor ligand. In the former
instance, the dissociation rate will seem slower than in
the latter, because the presence of a vast excess of un-
labeled orthosteric ligand used for isotopic dilution will
minimize the collision-limited re-binding of radioligand
to the receptor. In general, claims of cooperative binding
based on dissociation kinetic experiments using highly
expressed or concentrated receptor preparations need to
be viewed with caution due to the increased likelihood of
collision-limited binding.
In terms of functional assays of allosterism, some
methodological pitfalls that can mistakenly lead to
claims of allosteric phenomena include inadequate
equilibration times, heterogeneous receptor populations,
or nonequilibrium steady states (Kenakin, 1997c). In
particular, saturable agonist removal mechanisms (e.g.,
extraneuronal uptake and enzymatic breakdown) can
have profound effects on agonist potency; a cancellation
of these removal processes by a second ligand can en-
hance agonist potency and, thus, lead to the (false) claim
of “positive allosteric modulation” by the second drug.
An even more insidious problem in the interpretation
of allosteric phenomena from functional studies relates
to the nature of the conformational change in receptor
structure that the allosteric modulator produces. In ad-
dition to allosteric effects on orthosteric ligand affinity,
the functional quantification of allosteric interactions
using the ternary complex model is prone to the impact
of possible allosteric effects on stimulus-response cou-
pling. In the most obvious cases, this can be manifested
as an observed response to the allosteric modulator in
the absence of agonist. However, more subtle effects may
not be detected, such as those where the modulator
alters efficacy to affect the location of the concentration-
response curve but not the maximal attainable agonist
response or curve shape (Christopoulos, 2000a). As de-
scribed previously by Ehlert (1988), the maximal con-
centration-ratio to which an allosteric antagonist’s
Schild regression asymptotes is given by the product of
the cooperativity factor, , and the degree by which the
efficacy of the receptor in the ternary complex, ARB, is
altered by the modulator. Unless the modulator has no
effect on signaling efficiency, the value of  may be
erroneously determined from Schild analysis.
IV. Usefulness of Allosteric Modulators
There are distinct advantages to producing physiolog-
ical responses with allosteric ligands. The first is a satu-
rability of effect (Birdsall et al., 1996), because once the
allosteric sites are completely occupied, no further allo-
steric effect is observed. Thus, there is a “ceiling” to the
effects of an allosteric modulator that is retained irre-
spective of the dose that is administered therapeutically.
This is in contrast to orthosteric effects, which theoret-
ically can be infinite because they depend upon the
relative concentrations of the competing species. In the
latter circumstance, the duration of effect of competitive
drugs is inexorably linked to the magnitude of effect. For
a long duration of effect, a high concentration of the
competitive drug must be present to function as a depot.
However, this high concentration will also produce a
commensurately high magnitude of effect. In practice,
there must always be a trade-off between the dose of
competitive ligand that can be administered safely and
the desired concentration reaching the receptor com-
partment. As a consequence, the desired steady-state of
antagonism may not be achieved at the site of action due
to the interplay between dosage regimen, safety profile,
and pharmacokinetics. This codependence of kinetics
and effects, however, is not relevant to allosteric drugs.
In the latter instance, a very high concentration of allo-
steric ligand would serve as a depot for binding to the
allosteric site but the maximal effect will be defined by
the cooperativity factor for the ligand, namely the max-
imal degree of perturbation to the receptor produced by
the allosteric ligand. As a consequence, allosteric mod-
ulators would be generally much safer in overdosage
than orthosteric ligands, and they can be given in quite
high doses if necessary to maintain adequate receptor
concentrations without fear of overstimulating or over-
inhibiting receptor function.
A second advantage of positive allosteric modulators
relates to their ability to selectively “tune” tissue re-
sponses in those organs where the endogenous agonist
exerts its physiological effects (Birdsall et al., 1996).
Because neurohumoral signaling involves the pulsatile
release of hormones and variations in the activity of
nerves that release neurotransmitters, an allosteric
modulator would only be expected to exert its effects
when endogenous agonist is present. For example, the
actions of benzodiazepines, which potentiate the effects
of the endogenous neurotransmitter -aminobutyric
acid, depend only on the presence of the neurotransmit-
ter for activity (Holzgrabe and Mohr, 1998). If nerve
activity is reduced, an allosteric modulator would, thus,
have minimal effects, despite its continued presence in
the receptor compartment. This is not possible with or-
thosteric agonists, which will continuously modify recep-
tor function as long as they are present. Thus, allosteric
modulators can process the information gained from the
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physiology of the system to produce optimum effect, both
spatially and temporally.
The ability of allosteric modulators to tune normal
physiological signaling reflects a fundamental difference
between the type of agonism that can be obtained as a
consequence of direct activation of the orthosteric site on
a GPCR as opposed to that produced by an allosteric
enhancer. This difference relates to the attainment of a
particular response level through agonist concentration
augmentation as opposed to agonist concentration-re-
sponse enhancement and may be illustrated with an
important example. Neurodegenerative disorders, such
as Alzheimer’s disease, result in a progressive decline in
neuronal function, with one consequence often being a
decline in receptor-neurotransmitter responsiveness.
Standard neurotransmitter replacement therapies tar-
get the orthosteric site; this is a specific example of
concentration augmentation, where the concentration of
agonist is increased to overcome the deficit associated
with the neurodegenerative disorder. However, each in-
dividual neuron will have its own stimulus-response
coupling profile that can differ from adjacent neurons,
even though they each express the same receptor type.
Thus, the augmentation approach can result in over-
stimulation of some neurons and understimulation of
others. In contrast, the addition of an allosteric modu-
lator that uniformly sensitizes the system by a given
factor (i.e.,  value) will result in response enhancement
for the same concentration of endogenous neurotrans-
mitter present at each neuron; no augmentation is re-
quired, and the resulting levels of neurotransmitter re-
sponsiveness can be corrected more closely toward
normal levels.
Finally, allosteric ligands offer the possibility of “ab-
solute subtype selectivity” in receptor action by one (or
both) of two mechanisms. The first relates to the fact
that allosteric sites are necessarily different from ortho-
steric sites, and it is, thus, quite conceivable that many
receptors may show a greater divergence in sequence
homology in the domains that define the allosteric site in
contrast to the orthosteric site. In essence, the entire
receptor surface (other than the orthosteric binding do-
main) becomes a potential binding site for an allosteric
modulator. The likelihood of subtype-selectivity is,
therefore, enhanced if drug discovery programs target
receptor allosteric sites. The second mechanism for se-
lectivity is related to cooperativity rather than affinity.
Because the affinity of a modulator for its binding site is
not correlated with the degree of cooperativity that ex-
ists between orthosteric and allosteric sites, a modulator
may display the same affinity for each subtype of a
receptor but still exert a selective effect by having dif-
ferent degrees of cooperativity at each subtype. Absolute
subtype selectivity may, thus, be obtained where a mod-
ulator remains neutrally cooperative at all receptor sub-
types except the one targeted for therapeutic purposes.
Table 7 shows data obtained for the allosteric modula-
tor, N-chloromethylbrucine, at each of the five subtypes
of muscarinic acetylcholine receptor when tested against
acetylcholine. Although the affinity for the allosteric site
at each receptor subtype was within a 5-fold range of
values for N-chloromethylbrucine, the cooperativity fac-
tors were quite different. This compound was positively
cooperative with acetylcholine at the M3 receptor, neg-
atively cooperative at the M1 and M2 receptors, and
effectively neutrally cooperative at the M4 receptor.
Thus, some degree of absolute selectivity had been
achieved.
It may of course be argued that the relative paucity of
currently available allosteric modulators of GPCRs at-
tests to the difficulty in actually realizing the theoretical
advantages outlined in the preceding paragraphs. How-
ever, this paucity can also reflect the fact that most drug
discovery to date has been biased toward orthosteric
ligands (see section I). GPCRs react to an incredibly
wide range of endogenous ligands, from small entities
such as acetylcholine (muscarinic receptors) to large pro-
teins such as stromal derived factor (SDF-CXCR4 che-
mokine receptors). The likelihood that allosteric confor-
mational changes mediate the transfer of information
between GPCRs and these ligands is, thus, quite high.
In fact, it can also be argued that allosteric mechanisms
are prevalent in the action of many small “drug-like”
molecules (i.e., molecules of a low enough molecular
weight amenable to absorption by the oral route of ad-
ministration) that modify protein-protein interactions.
For example, M-tropic HIV is known to form syncytia
with cells (to produce subsequent viral infection)
through the interaction of the viral coat protein gp120,
the cellular single transmembrane protein CD4, and the
chemokine GPCR CCR5. Mutational studies have shown
that all four extracellular domains of the CCR5 receptor
(blockade of which is not amenable to orthosteric inter-
ference by a small single structure), interact with viral
coat protein to promote fusion (Rucker et al., 1996; Doms
and Peiper, 1997; Doranz et al., 1997; Picard et al., 1997;
Lee et al., 1999). Single-point mutations of CCR5 have
been unsuccessful in preventing HIV-1 fusion, also indi-
cating the involvement of multiple receptor domains in
HIV-1 binding (Doranz et al., 1997). Experiments with
chimeric CCR-5 have shown that the regions of the
receptor that interact with the endogenous chemokine
agonist MIP-1 (macrophage inflammatory protein type
TABLE 7
Affinity and cooperativity estimates for the allosteric modulator, N-
chloromethylbrucine, at the five subtypes of muscarinic acetylcholine
receptors
Subtype log[KA
1] 
M1 4.38 0.45
M2 4.22 0.094
M3 3.66 3.26
M4 4.32 1.03
M5 3.66 0.055
Data from Lazareno et al., 1998.
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1) differ from those that interact with HIV-1 gp120
(Blanpain et al., 1999a, 1999b; Howard et al., 1999), yet
it is well known that MIP-1 and other natural and
synthetic chemokines prevent HIV-1 infection in vitro
(Cocchi et al., 1995; Simmons et al., 1997; Mack et al.,
1998; Menten et al., 1999; Nishiyama et al., 1999). It
also is known that an allosteric enhancer of chemokine
function, trichosanthin, blocks HIV-1 infection through
potentiation of endogenous chemokines (Zhao et al.,
1999). Similarly, several nonpeptide molecules are
known to prevent HIV infection, including distamycin
analogs (Howard et al., 1998a, 1998b), bicyclams (Schols
et al., 1997; Labrosse et al., 1998), and, notably, TAK
779 (Baba et al., 1999). From these data it can be con-
cluded that small molecules can effectively inhibit the
interaction of large proteins through allosteric mecha-
nisms and that this can be a viable avenue for therapeu-
tic involvement.
The simplest hypothesis to explain how small struc-
tures can affect the binding of such huge protein do-
mains is by the stabilization of receptor conformations
that do not support viral entry. In terms of free energy,
a mechanism of conformational selection (whereby a
ligand selectively binds to a pre-existing receptor con-
formation thereby creating a bias toward that conforma-
tion) is preferable to a mechanism of conformational
induction (where the ligand actually creates the confor-
mation through binding). Differential affinities for dif-
ferent protein conformations will lead to enrichment of
the species for which the ligand has the highest affinity.
For example, assume a system of two receptor confor-
mations R and R* that coexist in the system according to
an isomerization constant denoted L (Fig. 2). For a li-
gand with a differentially greater affinity for the R*
form, introduction of [A] into the system will result in an
enrichment of the R* form. This can be shown by exam-
ining the amount of R* species (both as R* and AR*)
present in the system in the absence of ligand and in the
presence of ligand. The equilibrium expression for ([R*]

 [AR*])/[R], where [R] is the total receptor concentra-
tion given by the conservation equation [R]  [R] 
 [AR]

 [R*] 
 [AR*], is

 
L1  AKA 
A
KA
1  L 1  L
(26)
In the absence of agonist ([A]  0), 
0  L/(1 
 L), and in
the presence of a maximal concentration of ligand (sat-
urating the receptors; [A] 3 ) 
  (L)/(1 
 L). The
effect of the ligand presence on the ratio of R to R* is
given by 
/
0.



0

1  L
1  L (27)
It can be seen from eq. 27 that if the ligand has an
equal affinity for both the R and R* states (  1), then

/
0 will equal unity and no enrichment of the R* will
result from ligand binding. However, if   1, then the
presence of the conformationally selective ligand will
cause the ratio 
/
0 to be1. For example, if the affinity
of the ligand is 10-fold greater for the R* state, then in a
system where 20% of the receptors are spontaneously in
this state (L  0.1), the saturation of the receptors with
this agonist will increase the amount of R* by a factor of
2 (20–40%). By this mechanism, a small molecule such
as TAK779 could produce a bias in CCR5 receptor con-
formation to a conformation that does not support inter-
action of CCR5 with gp 120 viral coat protein. This, in
turn, would allow TAK 779 to prevent HIV-1 infection.
An alternative hypothesis can be described in which
the binding of the ligand actually deforms the receptor to
cause the formation of a new receptor conformation (i.e.,
conformational induction; see Burgen, 1981). It should
be noted that thermodynamically this is a much less
acceptable mechanism than conformational selection
where the conformation R* is already one of a library of
conformations known to the receptor. However, it should
also be pointed out that the enrichment of a rarely
formed spontaneously formed conformation through
conformational selection would be virtually indistin-
guishable as a mechanism from conformational induc-
tion (Kenakin, 1996b). In any case, the ever-expanding
list of small drug molecules that interfere with large
receptor-protein interactions suggests that clinically rel-
evant allosteric modulators of GPCRs are viable and
likely drug candidates; positive modulators of the extra-
cellular calcium-sensing GPCR, for instance, are already
in clinical trials (Conigrave et al., 2000a).
V. Location of the Allosteric Site(s)
A. Locks and Keys
In contrast to studies on ion channel-linked receptors,
there is a relative paucity of detailed structural informa-
tion regarding the amino acid composition of allosteric
sites on various GPCRs. Part of the difficulty relates to the
lack of sufficiently high-resolution crystallographic data of
GPCR structure for molecular modeling purposes, al-
though the recent publication of the X-ray crystal structure
of rhodopsin at 2.8-Å resolution (Palczewski et al., 2000)
may begin to redress this problem. Another difficulty is
related to the fact that GPCRs display a remarkable diver-
sity with respect to regions of the receptor protein that
constitute the primary, orthosteric domain; there is no
common orthosteric “lock” for agonist “keys” in GPCRs
(Schwartz and Rosenkilde, 1996). Figure 17 illustrates
some of the general modes of ligand binding for the three
main classes of the GPCRs. Endogenous orthosteric ago-
nists can bind within the transmembrane (TM) regions
(e.g., class I bioamine receptors), bind to both TM and
extracellular loop regions (e.g., class I neuropeptide recep-
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tors), or bind almost exclusively to the extracellular N-
terminal domain of the receptor (e.g., class I glycoprotein,
class II peptide, and class III metabotropic receptors). Fur-
thermore, many lipophilic drugs can approach the receptor
via the lipid membrane and, thus, interact with amino acid
regions at the lipid-protein interface, and some can even
interact with cytoplasmic regions (vide infra). Hence,
structural motifs that comprise the orthosteric site for one
type of GPCR ligand may in fact contribute to the allosteric
site of another type of GPCR ligand. A particularly striking
example of this phenomenon is evident from recent studies
on the metabotropic glutamate (mGluR) family of GPCRs.
In contrast to the rhodopsin-like class I receptors, the class
III mGluRs consist of two general topographical domains
that can be distinctly separated in terms of their contribu-
tions to ligand binding and receptor activation; a very large
extracellular N-terminal agonist binding domain and the
seven TM-spanning helices involved in receptor activation
and G protein coupling. The noncompetitive mGluR5 re-
ceptor antagonist, 2-methyl-6-(phenylethynyl)-pyridine
(MPEP), has been shown to have no effect on agonist
binding properties while being able to inhibit agonist-
mediated signaling (Gasparini et al., 1999; Pagano et al.,
2000; Spooren et al., 2001); this is a property shared with
another structurally unrelated mGluR1 antagonist, CPC-
COEt (Litschig et al., 1999). Interestingly, mutagenesis
experiments have identified crucial amino acids required
for MPEP binding in TM regions III and VII of the mGluR5
receptor, whereas no extracellular N-terminal regions ap-
pear necessary (Pagano et al., 2000; Spooren et al., 2001).
Furthermore, these amino acids are also necessary for the
binding of CPCCOEt, and both antagonists effectively
compete with one another. An additional important find-
ing is the fact that MPEP could reduce the basal activity of
constitutively active receptors mGluR5 receptors (Pagano
et al., 2000), whereas all known competitive antagonists of
these receptors have, to date, not demonstrated such in-
verse agonist properties. This raises the interesting con-
cept that for some receptors, a separation between neutral
antagonism and inverse agonism may be possible by tar-
geting drugs either to the orthosteric site (neutral mGluR
antagonists) or an allosteric site (inverse mGluR agonists)
that mediates receptor activation.
B. Modulation by Ions
Some allosteric sites on GPCRs may simply comprise
a single amino acid. A critical role for allosteric modu-
lation of GPCR function had been noted even before the
discovery of G proteins in the actions of certain mono-
valent cations, especially sodium. Subsequent mutagen-
esis studies identified an aspartic acid located in the
second TM domain (TMII) that is highly conserved
across GPCRs as being critical for agonist-mediated re-
ceptor function (Fraser et al., 1990; Horstman et al.,
1990; Neve et al., 1991; Strader et al., 1994). The nega-
tively charged aspartate acts as a counter-ion for the
positively charged sodium cation; a change in the charge
of this single TM amino acid can exert a global alteration
in GPCR conformational state that is transmitted both
to the agonist binding site and the G protein coupling
interface. This is an important example of a single con-
tact point on the receptor that may not form part of the
orthosteric binding site but can exert an allosteric effect
on the binding properties of both agonists and G pro-
teins.
The allosteric effects of sodium on GPCR binding and
coupling reflect the importance of the conserved TM II
aspartic acid in mediating conformational changes that
predominantly affect the activation state of the receptor;
agonists and inverse agonists are particularly suscepti-
ble to modulation by sodium ions when compared with
antagonists. Physiologically, the effects of sodium are
representative of changes in the intracellular accessibil-
ity of this ion to the receptor TM domains (Motulsky and
Insel, 1983; Horstman et al., 1990). However, other cat-
ions have been suggested to allosterically modulate
GPCR binding properties by interacting with extracel-
lular amino acid contact points. In a recent study, Schetz
and Sibley (1997) investigated the effects of 18 different
cations on the binding properties of the antagonists
[3H]SCH-23390 and [3H]methylspiperone at the cloned
human D1A or D2L receptors, respectively. They found
that the d-transition metals with a pseudonoble-gas con-
figuration (e.g., Cd2
, Zn2
, and Cu2
), and cations with
FIG 17. Modes of orthosteric ligand binding at GPCRs. A, for many
class I GPCRs, such as those for the bioamines, nucleotides, eicosanoids,
and lipid moieties, orthosteric binding occurs predominantly within the
transmembrane regions; the binding and activation events are inextrica-
bly linked. B, class I neuropeptide receptors use multiple attachment
points, involving both transmembrane and extracellular loop regions. C,
protease-activated receptors are unique to the class I GPCRs in that the
endogenous agonist forms part of the N-terminal region; this “tethered”
ligand is exposed after enzymatic cleavage of the extreme N-terminal
part of the tail; activation then proceeds through interaction with trans-
membrane regions. D, class I glycoprotein and class II peptide receptors
have large N termini that constitute the orthosteric binding site, al-
though activation involves subsequent contact with transmembrane re-
gions. E, class III metabotropic receptors possess the largest N-terminal
tails out of all GPCRs; orthosteric binding is exclusive to this region,
whereas activation involves the transmembrane domains. It is unlikely
that the ligand makes any contact with the transmembrane regions;
activation is, thus, determined solely by conformational changed across
the protein’s surface.
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a 3
 charge (Fe3
, Al3
, La3
, and Gd3
), all inhibited
antagonist binding. In particular, zinc is of interest be-
cause it has previously been suggested to serve a role in
the central nervous system in modulating protein-pro-
tein and protein-neurotransmitter interactions because
it has no redox activity and no ligand field stabilization
energy, is compartmentalized in certain neuronal syn-
aptic vesicles, and can accumulate extracellularly in the
synaptic cleft (Schetz and Sibley, 1997; Schetz et al.,
1999). The effects of zinc contrast from those of sodium
in that it quite clearly affects the binding of antagonists
that are insensitive to sodium (Schetz et al., 1999;
Schetz and Sibley, 1997; 2001). Figure 18 illustrates the
allosteric nature of the zinc effect on D1 and D2 recep-
tors, where it can be seen that increasing concentrations
of zinc progressively reduce antagonist binding affinity
with no change in the Bmax of the radioligand (Fig. 18, A
and C). Furthermore, the zinc-mediated reduction in
radioligand affinity approaches a limit over the concen-
tration ranges of modulator that were tested, thus, re-
vealing the negatively cooperative nature of the interac-
tion (Fig. 18, B and D). Importantly, recent studies on
the D4 dopamine receptor have demonstrated that the
effects of sodium, zinc, and the allosteric modulator MIA
occur through distinct attachment points (Schetz and
Sibley, 2001). Specifically, sodium was able to allosteri-
cally modulate the effects of zinc on antagonist binding,
whereas neither zinc nor sodium interacted with MIA.
However, a receptor mutation that modified the binding
properties of MIA had no effect on zinc. Thus, in addition
to the TMII aspartic acid known to be critical for the
modulatory properties of sodium, these studies with zinc
have highlighted the existence of at least two other loci
on dopamine receptors that are also targets for allosteric
modulation.
C. Interactions at the Receptor-G Protein Interface
In addition to the allosteric effects of G proteins on
orthosteric ligand binding, there are also examples of
ligands that can affect GPCR binding and coupling prop-
erties by interacting with intracellular receptor regions
thought to constitute the interface between the GPCR
and its G protein. For instance, there is a series of
polyanionic compounds that are well known for sharing
the common property of interacting with the predomi-
nantly cationic face of the amphipathic helical regions of
the GPCR-G protein interface. In particular, the poly-
sulfonic acid suramin has been extensively studied in
radioligand binding and signal transduction assays. As
well as acting as an orthosteric antagonist of purinergic
receptors (Ralevic and Burnstock, 1998), suramin has
been shown to uncouple opioid receptors (Butler et al.,
1988), 2- and 2-adrenoceptors (Huang et al., 1990),
and adenosine A1 and dopamine D2 receptors (Freiss-
muth et al., 1996) from their cognate G proteins. In
addition, these effects are associated with an inhibition
of agonist binding, whereas antagonist binding remains
unaffected (Huang et al., 1990) or is enhanced (Freiss-
muth et al., 1996). Interestingly, the effects of suramin
and a number of its analogs on orthosteric ligand bind-
FIG 18. Saturation binding of [3H]SCH-23390 at the D1A dopamine receptor (A) or [
3H]methylspiperone at the D2 dopamine receptor (C) in the
absence or presence of increasing concentrations of ZnCl2 (5 M–50 mM). Data in B and D show the data in A and C, respectively, converted to
Schild-type plots. Note the deviation from linearity at high zinc concentrations; the maximal dose-ratio is defined by the cooperativity factor, . Data
taken from Schetz and Sibley (1997).
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ing are absent in receptor systems devoid of G proteins
or in systems where the G proteins have been previously
uncoupled, for instance, by treatment of the prepara-
tions with stable GTP analogs (Huang et al., 1990; Fre-
issmuth et al., 1996). The latter findings raise important
questions regarding the intracellular contact sites of
such polyanionic modulators of receptor function. Al-
though an impedance of receptor-G protein coupling by
these ligands is strongly supported by available data, it
is still unclear as to whether the binding of these com-
pounds occurs predominantly on the receptor, on the G
protein, or equally well to both. The lack of polyanionic
modulator effects on the binding properties of uncoupled
receptors suggests that the interaction between these
modulators and the receptor’s orthosteric site, if it ex-
ists, must be neutrally cooperative in nature and only
manifested indirectly through receptor-G protein cou-
pling block. Furthermore, it is known that suramin can
actually bind to a distinct site on G protein -subunits in
the absence of any receptor coupling to modify nucleo-
tide binding properties (Beindl et al., 1996). Thus, it is
possible that the allosteric effects of polyanionic modu-
lators such as suramin are mediated predominantly
through their effects on G protein contact points.
D. Extracellular Allosteric Sites
In comparison with compounds that require access to
an intracellular site of action, small molecule allosteric
modulators that can target extracellular binding sites on
a GPCR are particularly attractive targets in terms of
drug discovery and therapeutics. Studies of extracellular
binding domains of allosteric modulators have generally
exploited receptor mutagenesis and/or the construction
of receptor chimeras. It should be noted, however, that
these approaches are most useful when undertaken in
light of experimental evidence indicating the presence of
a distinct allosteric binding site on the receptor that can
be recognized by more than one type of allosteric modu-
lator. This is not a trivial point, because many ligands
have the ability to nonspecifically perturb receptor con-
formation, for instance through effects on the surround-
ing lipid bilayer, and, thus, be mistakenly labeled as
“allosteric modulators”.
To date, investigations on the localization of an extra-
cellular allosteric site for small molecules and drugs at
class I GPCRs have been predominantly focused on stud-
ies of the muscarinic acetylcholine receptor family. This
is in no small part due to strong evidence in favor of a
distinct and common allosteric site recognized by more
than one type of modulator. For example, Fig. 19A shows
the interaction between the allosteric modulators gal-
lamine or TMB-8 and the modulator, obidoxime, at the
M2 muscarinic acetylcholine receptor. Under the exper-
imental conditions of the assay, gallamine allosterically
enhances the observed dissociation rate of the orthos-
teric antagonist, [3H]quinuclidinyl benzilate ([3H]QNB),
TMB-8 reduces [3H]QNB dissociation, whereas obi-
doxime has a minimal effect. However, when the allo-
steric effects of gallamine or TMB-8 are monitored in the
presence of obidoxime, a concentration-dependent rever-
sal of these effects is noted. Importantly, the entire
dataset could be fitted to a model assuming competition
between all three modulators for a single allosteric site
(Ellis and Seidenberg, 2000). Even more direct evidence
for the presence of a specific allosteric site on muscarinic
receptors has been facilitated by the synthesis of the
FIG 19. A, reversibility of the allosteric effects of gallamine or TMB-8
by obidoxime at the human M2 muscarinic acetylcholine receptor. Data
are expressed as the ratio of the apparent [3H]QNB dissociation rate in
the presence (kobs) and absence (k0) of allosteric modulator. Note that the
accelearting effects of gallamine and the retarding effects of TMB-8 on
radioligand dissociation are equally inhibited by obidoxime. The entire
dataset was fitted to a model assuming competition between the three
modulators for a common allosteric site. Data taken from Ellis and
Seidenberg (2000). B, Binding properties of the modulator, gallamine, at
the M2 muscarinic receptor as determined either indirectly, using
[3H]NMS to label the orthosteric site, or directly, using [3H]dimethyl-W84
to label the allosteric site. The ratio of gallamine affinities between the
free and NMS-occupied receptor corresponds to the cooperativity factor,
, in the simple allosteric ternary complex model when fitted to the
[3H]NMS binding data. Labeling of the allosteric site with [3H]dimethyl-
W84 to directly determine gallamine affinity at this site reveals an
affinity shift (pKI shift) of gallamine for the free versus the NMS-occupied
receptor that is identical with the cooperativity factor determined from
the [3H]NMS experiments. The value of pK is defined as the negative
logarithm of the apparent dissociation constant. Data taken from Tra¨nkle
et al. (1999).
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radiolabeled allosteric modulator [3H]dimethyl-W84
(Tra¨nkle et al., 1998), which binds with sufficiently high
affinity to the M2 receptor to allow direct testing of the
simple allosteric ternary complex model. Figure 19B
shows estimates of gallamine’s binding affinity for the
free and the NMS-occupied M2 receptor determined us-
ing either [3H]NMS as the orthosteric tracer or [3H]di-
methyl-W84 as the allosteric tracer. It can be seen that
in either instance, the affinity estimates for gallamine
were indistinguishable whether determined in direct
competition with the allosteric radioligand or through
indirect interaction with the orthosteric radioligand
(Tra¨nkle et al., 1999). Additional studies by others using
equilibrium binding, dissociation kinetics, and func-
tional bioassays have also yielded data with respect to a
large range of muscarinic allosteric modulators that are
in accord with interaction at a common site (for review,
see Christopoulos et al., 1998). It should be noted that
similar approaches have also been used, although to a
more limited extent, to demonstrate the existence of a
common allosteric site for multiple modulators on dopa-
mine D2 receptors (Hoare and Strange, 1996), 1-adre-
noceptors (Leppik et al., 2000), and 2-adrenoceptors
(Leppik et al., 1998; Leppik and Birdsall, 2000).
The types of observations outlined above have pro-
vided impetus for detailed studies on the location of the
muscarinic acetylcholine receptor allosteric site. In par-
ticular, gallamine has been used in almost all such stud-
ies as the prototypical muscarinic allosteric modulator,
and experiments aimed at delineating the location of the
allosteric site on muscarinic receptors have targeted
residues thought to be involved in the binding of this
modulator. The known abilities of gallamine to i) impede
access to and egress from the orthosteric binding site
(Birdsall et al., 1996), ii) protect the orthosteric site from
chemical modifications (Jakubı´k and Tucek, 1994), and
iii) rapidly produce allosteric effects in intact cells and
whole tissues (Christopoulos et al., 1998) suggest that
the allosteric site comprises extracellular contact points
located above the orthosteric site, which is itself postu-
lated to be located in the upper one-third of the inner
transmembrane pore (Wess, 1993). In general, molecu-
lar biological approaches have either focused on regions
conserved across the five muscarinic receptor subtypes
or specifically focused on nonconserved residues; each of
these approaches has its own advantages. For instance
mutagenesis of conserved amino acids can yield infor-
mation about allosteric site(s) common to all muscarinic
receptors, whereas studies on nonconserved amino acids
can provide insight into subtype-selective allosteric
modulators.
In one of the earliest mutagenesis studies on musca-
rinic receptor allosteric sites, Lee et al. (1992) modified a
series of conserved aspartate residues in the M1 receptor
and found that substitution of Asp713Asn decreased
the affinity of gallamine for the receptor, and the mag-
nitude of its cooperativity with [3H]NMS. Substituting
Asp993Asn slightly increased gallamine’s affinity, but
the cooperativity remained unchanged, whereas
Asp1213Asn resulted in no difference when compared
with the wild-type receptor. In another study, Matsui et
al. (1995) found that mutations of Trp1013Ala and
Trp4003Ala in the outer portions TMIII and TMVII,
respectively, of the M1 receptor produced greater effects
on the affinity of gallamine for the receptor than the
mutation of Asp71 described by Lee et al. (1992). How-
ever, an investigation of the role of Asn residues in the
M2 receptor by Leppik et al. (1994) was in accordance
with the earlier M1 study of Lee et al. (1992), in that
mutation of the conserved Asp69 in TMII was found to
play a role in gallamine’s binding. More significantly,
however, a mutation of the EDGE sequence (Glu172-
Asp173-Gly174-Glu175) in the second extracellular loop
led to marked alterations in gallamine’s ability to allos-
terically modulate [3H]NMS binding (Leppik et al.,
1994). This particular sequence of amino acids is unique
to the M2 receptor, although it should be noted that
every muscarinic receptor subtype, except for the M1
receptor, has at least one acidic amino acid in the corre-
sponding region (Ellis, 1997). Furthermore, substitution
of the EDGE sequence into the second extracellular loop
of the M1 receptor conferred significantly higher affinity
of gallamine for that receptor, thus, confirming that the
allosteric site on muscarinic receptors requires specific
extracellular contact points and is especially sensitive to
acidic amino acids (Gnagey et al., 1999).
In a complementary series of studies, Ellis and col-
leagues have constructed a series of chimeric muscarinic
receptors to probe the location of the allosteric site.
Based on the large separation of gallamine’s affinity
between the M2 receptor, on the one hand, and the M5 or
M3 receptors, on the other. Chimeric receptor constructs
of M2/M5 and M2/M3 receptors identified broad regions
of amino acids responsible for gallamine’s allosteric
properties (Ellis, 1997). A 31-amino acid stretch incor-
porating parts of the third extracellular loop and TMVI
of the M2 receptor was necessary for gallamine’s effects,
which was in line with the observations of Matsui et al.
(1995) because this stretch incorporated Trp400. How-
ever, the extension of these studies to the actions of
other allosteric modulators, such as TMB-8, has subse-
quently identified additional epitopes as being impor-
tant for allosteric potency, with a single threonine (T423)
residue at the M2 receptor playing a critical role in
defining subtype selectivity for a number of muscarinic
acetylcholine receptor modulators (Ellis and Seidenberg,
2000; Buller et al., 2002)
Taken together, the available data suggest that the
allosteric binding site for many charged molecules on
muscarinic acetylcholine receptors may be somewhere
close to the orthosteric site, but at a more extracellular
level. Because allosteric interactions are evident at all
five subtypes, conserved residues such as Trp101, Trp400,
and possibly Asp71 (using the M1 receptor designation)
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may play fundamental roles in allosteric modulation of
the receptor such as ligand recognition and/or mainte-
nance of a favorable conformation. The EDGE sequence,
unique to the M2 receptor, may provide a further extra-
cellular point of attraction and stabilization, and this
may explain why the M2 receptor seems to be the most
readily modulated. It is likely that epitopes in the second
and third outer loops of the receptors that contain acidic
amino acids play a fundamental role in providing sub-
type-selectivity for different muscarinic allosteric mod-
ulators (Ellis and Seidenberg, 2000). Most recently, pre-
liminary molecular modeling of the M1 receptor, based
on 2.8-Å crystal structure of rhodopsin (Palczewski et
al., 2000), has found general agreement with the preced-
ing speculations (Birdsall et al., 2001). In particular, a
region of conserved extracellular residues above TMs V
to VII form a cleft that contains Trp400, Ser388, Asp393,
and Glu397, acidic residues in the third extracellular loop
important for gallamine binding (Gnagey et al., 1999). It
is possible that this cleft forms an entrance to the ortho-
steric binding site and can explain the dramatic slowing
effects many muscarinic allosteric modulators have on
orthosteric ligand kinetics. Unfortunately, detailed
structural information regarding the allosteric sites on
class I GPCRs other than the muscarinic acetylcholine
receptors is currently lacking.
1. Multiple Allosteric Sites. Not all of the data de-
rived from studies on GPCR allosterism are compatible
with the notion of a single extracellular allosteric site in
addition to the orthosteric site. For instance, gallamine
and tubocurarine exert biphasic effects on the dissocia-
tion of [3H]QNB at M2 muscarinic receptors in low ionic
strength media, first enhancing and then retarding ra-
dioligand dissociation depending on the concentration of
modulator used (Ellis and Seidenberg, 1989; Ellis et al.,
1991). These data are difficult to explain without postu-
lating the existence of two separate allosteric sites that
the modulators recognize with different affinities. Other
examples include the green mamba venom “m1-toxin”,
which forms an almost irreversibly bound cap across the
extracellular regions of the M1 muscarinic receptor by
using multiple binding points (Max et al., 1993), and
different attachment points have also been suggested for
a series of hexamethonium derivatives (Bejeuhr et al.,
1994) and unilaterally ring-substituted bispyridinium
derivatives (Kostenis et al., 1996) on M2 muscarinic
receptors. Significantly, the anticholinesterase tetrahy-
droaminacridine (THA) consistently results in inhibition
curves with slopes steeper than unity for various ortho-
steric radioligands at muscarinic receptors (Flynn and
Mash, 1989; Potter et al., 1989; Kiefer-Day et al., 1991;
Mohr and Tra¨nkle, 1994). The simplest scheme to ac-
commodate these results would involve THA recognizing
both the orthosteric and allosteric sites but only exerting
positive cooperativity with respect to its own binding.
Alternatively, THA may recognize two modulatory sites,
each interacting positively co-operative with one an-
other and negatively cooperative with the orthosteric
site.
Figure 20 shows the results from a series of radioli-
gand dissociation kinetic experiments performed at the
M2 muscarinic receptor using a variety of allosteric mod-
ulators; the data are plotted in the form of Schild regres-
sions. It can be seen that the weak modulator, obi-
doxime, was able to concentration-dependently inhibit
the allosteric effects of gallamine, W84, alcuronium, and
WDuo3 and that the estimates of obidoxime’s affinity for
the allosteric site were in general agreement in each
case (Tra¨nkle and Mohr, 1997). However, the interaction
between obidoxime and the modulator, Duo3, is charac-
terized by a significantly lower pA2 value, strongly sug-
gestive of interaction at a different allosteric site. Un-
fortunately, one of the limitations of using ligands such
as obidoxime is that its low affinity for the allosteric
site(s) limits the concentration ranges over which it can
be tested. More recent studies have identified the indo-
locarbazole, KT5720, as a relatively high-affinity allo-
steric modulator of M1 muscarinic receptors that shares
obidoxime’s ability of exerting minimal effects on ortho-
steric ligand dissociation kinetics while maintaining the
ability to bind to an allosteric site (Lazareno et al.,
2000). This important property has been used in combi-
nation experiments monitoring the interaction between
KT5720 and [3H]NMS in the absence or presence of
acetylcholine and other allosteric modulators such as
gallamine and brucine. Surprisingly, it was found that
FIG 20. Schild plots of the interaction between the allosteric modula-
tor, obidoxime, and other modulators at the M2 muscarinic acetylcholine
receptor. Dose ratios (DR) were calculated as the concentration of indi-
cated allosteric modulator producing half-maximal slowing of [3H]NMS
dissociation from the receptor in the absence to that obtained in the
presence of increasing concentrations of obidoxime. The interaction be-
tween obidoxime and Duo3 is not consistent with binding to a common
allosteric site recognized by the other modulators. Data taken from
Tra¨nkle and Mohr (1997).
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KT5720 could bind simultaneously to the receptor with
gallamine or brucine and orthosteric ligands. The inter-
action between KT5720 and gallamine or brucine was
neutrally cooperative, whereas it exerted positive coop-
erativity with [3H]NMS and acetylcholine. Thus, the
presence of two distinct allosteric sites has been sug-
gested for the M1 receptor.
Recent data also suggest that more than one allosteric
site exists on the 1-adrenoceptor. For example, the al-
losteric modulator 5-(N,N-hexamethylene)-amiloride en-
hances [3H]prazosin dissociation at the human 1-adre-
noceptor, but the data cannot be fitted to the simple
allosteric TCM (Leppik et al., 2000). However, an exten-
sion of the allosteric model to incorporate two binding
sites for 5-(N,N-hexamethylene)-amiloride on the 1-re-
ceptor can adequately accommodate the entire dataset.
Finally, it is possible that other highly conserved al-
losteric sites may be present on many GPCRs. Table 8
lists the inhibition binding parameters for the novel
thiadiazole compound N-(2,3-diphenyl-1,1,4-thiadiazol-
5-(2H)-yildene)methenamine at a range of class I
GPCRs. This compound inhibits the binding of both ago-
nists and antagonists with low micromolar potency at
these receptors in a reversible manner that is indepen-
dent of receptor-G protein coupling (Fawzi et al., 2001).
This is in contrast to other general modulators of GPCRs
such as suramin (see above) that lose their allosteric
properties in the absence of G proteins. Furthermore,
the inhibition of orthosteric binding by N-(2,3-diphenyl-
1,1,4-thiadiazol-5-(2H)-yildene)methenamine is accom-
panied by a concentration-dependent reduction in radio-
ligand Bmax values, thus, suggesting a noncompetitive
mode of binding. Overall, however, the presence of a
distinct and conserved allosteric site for small molecules
at a variety of class I GPCRs is still mostly speculative at
the moment and remains to be further investigated.
VI. Endogenous Allosteric Modulators
By definition, the orthosteric binding site on a GPCR
comprises amino acids that form contacts with the en-
dogenous agonist for that receptor; this site has, thus,
specifically evolved to interact with an endogenous hor-
mone or neurotransmitter. In contrast, allosteric bind-
ing sites need not satisfy this criterion. These latter sites
may simply represent accessory domains normally serv-
ing structural roles, and it is only with the discovery of
exogenous ligands (e.g., drugs) that recognize these do-
mains that allosteric modulation of receptor function
becomes biologically relevant. However, it is well known
that certain GPCR amino acid contact points are critical
for recognizing endogenous cations and transmitting
global conformational changes that affect orthosteric li-
gand and/or G protein binding (see above). More signif-
icantly, ion-channel-linked receptors are known to be
allosterically modulated by a number of endogenous li-
gands. For example, the GABAA receptors possess a
distinct allosteric binding site for neuroactive steroids
such as pregnanolone (Gasior et al., 1999). Thus, it is
possible that some GPCRs may also normally interact
with endogenous allosteric modulators under physiolog-
ical or perhaps pathophysiological conditions.
One candidate for an endogenous allosteric modulator
of GPCR function is the tetrapeptide LSAL, termed “5-
HT-moduline”. This substance was originally isolated
from rat brain and has been shown to interact with the
5HT1B autoreceptor with high affinity. In contrast, it
does not have appreciable affinity for a variety of other
5HT and non-5HT receptors (Fillion et al., 1996; Massot
et al., 1996). Interestingly, the interaction between
5-HT-moduline and either 5HT agonists or antagonists
is noncompetitive and antagonistic in nature. In radio-
ligand binding assays, 5-HT-moduline causes a reduc-
tion in the maximal attainable level of orthosteric bind-
ing and in assays of receptor function, it causes a
reduction in maximal agonist responsiveness (Fillion et
al., 1996; Massot et al., 1996). Importantly, this peptide
demonstrates a regional distribution similar to that of
5HT1B receptors, is released from nerve terminals in a
Ca2
- and K
-dependent manner and is rapidly de-
graded by enzymatic breakdown (Massot et al., 1996;
Cloez-Tayarani et al., 1997). Taken together, these cri-
teria suggest a true neuromodulatory role for 5-HT-
moduline, and a physiological role in stress conditions
has also been postulated (Massot et al., 1998).
Other endogenous substances have been identified as
possible allosteric modulators of muscarinic acetylcho-
line receptors. For example, Heron and Schimerlik
(1984) suggested the presence of a nondialyzable, pro-
tease-sensitive factor in atria that reversibly affected
the association kinetics of [3H]QNB. Another substance,
termed “endogenous soluble factor”, was isolated from
embryonic chick heart by Creazzo and Hartzell (1985)
and found to decrease [3H]QNB binding in a noncompet-
itive manner. The authors suggested a possible role in
agonist-induced desensitization and receptor down-reg-
ulation. Diaz-Arrastia et al. (1985) identified a low-mo-
lecular weight peptide, P2F, in calf thymus that also
antagonized [3H]QNB noncompetitively. Various re-
searchers have identified other endogenous protein mod-
ulators of muscarinic receptors (Maslinski et al., 1988;
TABLE 8
Inhibitory potency of the noncompetitive antagonist, SCH-202676, on
the orthosteric binding of different Class I GPCRs
Receptor Radioligand IC50
M
-Opioid [3H]Diprenorphine 0.3
-Opioid [3H]Diprenorphine 1.7
-Opioid [3H]Diprenorphine 1.8
M1 muscarinic [
3H]N-methylscopolamine 0.4
M2 muscarinic [
3H]N-methylscopolamine 0.4
2A-Adrenergic [
3H]Yohimbine 0.5
1-Adrenergic [
125I]Iodocyanopindolol 1.2
D1 dopamine [
3H]SCH-23390 0.1
D2 dopamine [
3H]Methylspiperone 0.1
Adapted from Fawzi et al., 2001.
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Fryer and El-Fakahany, 1989; Fang et al., 1993; Frey et
al., 1994, 1996). One particularly interesting finding
was the possible modulatory role that human eosinophil
major basic protein may play in M2 receptor dysfunction
of the airways (Jacoby et al., 1993). This raises the
possibility of a pathophysiological role of endogenous
muscarinic allosteric modulators in disorders such as
asthma. Other endogenous cationic peptides such as
protamine (Hu et al., 1992) and dynorphin-A (Hu and
El-Fakahany, 1993) have also demonstrated allosteric
effects on muscarinic receptors.
Another example of pathophysiological conditions
that may be mediated by allosteric regulation of GPCR
function can be found in a variety of cardiac neuro-
myopathies characterized by the production of receptor
autoantibodies. For instance, the chronic stage of the
parasite-transmitted Chagas’ disease, one of the most
common determinants of congestive heart failure in the
world, involves the endogenous generation of antibodies
that interact with and persistently activate -adrenergic
and muscarinic acetylcholine receptors (Leiros et al.,
1997). Previous studies with antibodies raised against
specific GPCRs have identified the second extracellular
loop of these receptors as a site of antibody binding that
also leads to receptor activation (AbdAlla et al., 1996;
Mijares et al., 1996, 2000). In the case of peptide recep-
tors, such as the bradykinin B2 receptor, the antibody
contact points in the extracellular loop may constitute
part of the orthosteric site (AbdAlla et al., 1996). How-
ever, for antibodies raised against the class I bioamine
receptors, this is unlikely (Tucek, 1997). Hence, the ac-
tivation and subsequent desensitization of -adrenergic
and muscarinic acetylcholine receptors mediated by en-
dogenously produced Chagasic autoantibodies (Leiros et
al., 1997) may be mediated by an allosteric mechanism.
Perhaps not surprisingly, most candidate endogenous
allosteric modulators of GPCRs identified thus far are
peptides. However, this is not always the case. Oleamide
is an amidated lipid found in cerebrospinal fluid that
plays an important role in sleep regulation (Boger et al.,
1998). However, this substance also has distinct effects
on 5HT2 and 5HT7 receptors that are due to interaction
with an allosteric site. For instance, at the 5HT2A recep-
tor, oleamide potentiates agonist-mediated PI hydroly-
sis, whereas at the 5HT7 receptor, it is able to modify
receptor signaling even in the absence of agonist; impor-
tantly, this latter effect of oleamide is resistant to an-
tagonism by the orthosteric antagonist clozapine (Thom-
as et al., 1997). The allosteric binding properties of
oleamide at the 5HT7 receptor have also been demon-
strated in radioligand binding assays (Hedlund et al.,
1999), thus, identifying this agent as a novel neuro-
modulator of GPCR function.
With the possible exception of the muscarinic acetyl-
choline receptors (see preceding section) and some of the
class III GPCRs, the overall lack of specific structural
information about the allosteric pharmacophore(s) of
other GPCRs means that the identification of possible
endogenous allosteric modulators still relies on a pre-
dominantly empirical approach. Nevertheless, it is pos-
sible that changes in cellular homeostatic mechanisms,
for example due to disease, are mediated in part by
alterations in the type and/or level of endogenous sig-
naling molecules that interact with GPCRs in an allo-
steric manner.
VII. G Protein-Coupled Receptor Complexing
Protein-protein interactions constitute the core intra-
cellular signaling motif in all living systems. Sometimes,
interactions between protein partners are transient,
perhaps serving a catalytic role, whereas other times
they involve the formation of more stable and longer-
lasting multimeric complexes. In all instances, however,
the formation of a bond between two proteins causes a
conformational change that can ultimately determine
the functional consequence of the interaction. If the re-
sulting multimeric complex displays altered properties
with respect to its subsequent interactions with other
ligands or proteins, then the potential exists for alloste-
ric interactions to occur between the various binding
sites on the complex.
By their very nature, GPCRs participate in a requisite
coupling to other membrane components, most notably
G proteins, to transduce the stimulus imparted to the
receptor by an agonist to the cell. As discussed earlier,
this interaction is characterized by allosteric effects
transmitted between binding sites on either protein.
From the perspective of the GPCR, the orthosteric site is
the agonist binding site, whereas for the G protein, the
orthosteric site may be defined as the guanine nucleo-
tide binding site on the G-subunit. The binding inter-
face between the two proteins constitutes the allosteric
site. Although this description ignores the additional
allosteric effect that can occur as a consequence of G
protein -subunit binding (Onaran et al., 1993), it is
nevertheless sufficient to illustrate the best studied ex-
ample of GPCR complexing. Beyond the G protein par-
adigm, however, GPCRs have generally been considered
to behave as monomeric proteins with respect to their
interactions with orthosteric ligands. Even the examples
of allosterism illustrated in the preceding sections are
all instances of where more than one binding site is
located on the receptor monomer, and allosteric behavior
arises as a consequence of interactions between these
sites. More recently, the classic picture of GPCRs as
monomers has been reevaluated due to the realization
that they can form complexes with proteins other than G
proteins. The most compelling evidence comes from the
increasing number of studies demonstrating the ability
of GPCR monomers to combine and form dimers, or even
higher order oligomers, but studies are now expanding
the list of “accessory proteins” that may act as partners
with GPCRs in an array of signaling complexes. In all of
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these instances, the possibility exists for allosterism as a
consequence of protein-protein interactions.
A. Receptor-Receptor Interactions
In contrast to GPCRs, receptors from other superfami-
lies have long been known to form multimeric complexes
to participate in cellular signaling. For example, mem-
bers of the growth factor receptor family such as the
EGF-R, PDGF-R, FGF-R, and interferon -receptors
have been identified as structural and functional dimers
(see Hebert and Bouvier, 1998). Ion-channel linked re-
ceptors are also known to exist as hetero-oligomers, that
is, they are composed of multiple subunits of different
protein types, thus, leading to a diverse array of receptor
subtypes (Galzi and Changeux, 1994). Each of these
instances can lead to cooperative behavior if more than
one molecule of the orthosteric ligand is able to bind to
the multimeric receptor complex.
Indirect evidence has also been available for coopera-
tive binding of orthosteric ligands at GPCRs for quite
some time. For instance, radioligand binding assays at
the 2-adrenoceptor (Limbird et al., 1975), the musca-
rinic receptors (Mattera et al., 1985; Lee et al., 1986;
Potter et al., 1988, 1991; Henis et al., 1989; Wregget and
Wells, 1995; Chidiac et al., 1997), and the histamine
receptor (Steinberg et al., 1985a, 1985b, 1985c; Sinkins
et al., 1993; Sinkins and Wells, 1993) have often de-
scribed orthosteric binding properties that could not be
readily reconciled either with simple mass-action mono-
meric receptor behavior or within the framework of a
simple ternary complex model between orthosteric li-
gand, receptor, and G protein. For example, Fig. 21A
shows the binding of the orthosteric agonist oxotremo-
rine-M against the antagonist [3H]AF-DX 384 at native
M2 muscarinic receptors. In the presence of G protein
coupling, the competition curve is inhibitory (circles),
although it is characterized by a biphasicity that sug-
gests multiple affinity states. Interestingly, when the
nonhydrolyzable GTP analog Gpp(NH)p is included in
the assay to uncouple receptor-G protein complexes, a
distinctly bell-shaped binding curve (squares) is ob-
tained for the agonist-antagonist interaction, character-
ized by an initial element of positive cooperativity. Given
that both ligands recognize the orthosteric site of the
muscarinic receptor, this pattern cannot be reconciled
with the simple TCM of allosteric interaction described
earlier, nor with the ternary complex model of orthos-
teric ligand-receptor-G protein. This behavior can be
rationalized, however, if it is assumed that GPCRs can
exist as dimers within the cell membrane. A simple
model of receptor dimerization is illustrated in Scheme
3, where R represents a dimerized receptor (e.g., R-R), A
and B represent orthosteric ligands that can bind to
either or both orthosteric sites on the dimer, and Ka and
Kb denote the equilibrium association constants for
binding of either ligand to a vacant dimer. The symbol 
denotes the cooperativity factor for the binding of a
second equivalent of ligand A to a dimer that is already
occupied by a molecule of A, the symbol  denotes the
cooperativity factor for the binding of a molecule of li-
gand B to a dimer that is already occupied by a molecule
of A, whereas the symbol  denotes the cooperativity
factor for the binding of a second equivalent of ligand B
to a dimer that is already occupied by a molecule of B.
The receptor conservation equation for this scheme is as
follows.
RT  R 2AR 2BR 2ARB ARA
 BRB (28)
FIG 21. A, interaction between the orthosteric agonist, oxotremo-
rine-M, and the orthosteric antagonist, [3H]AF-DX 384, at the M2 mus-
carinic acetylcholine receptor copurified with G proteins from porcine
sarcolemmal membranes. The data were obtained in the absence (E) or
presence () of the nonhydrolyzable GTP analog, Gpp(NH)p. Curves
through the data represent the best fit based on a model of receptor
oligomerization. Data taken from Wregget and Wells (1995). B, predicted
behavior of a dimeric receptor system. Effects of orthosteric ligand B on
the binding of orthosteric ligand A according to eq. 29 with the following
parameter values pKA  9, pKB  8, and log[A]  7. The cooperativity
factors shown in the figure represent the interaction between two mole-
cules of A (), two molecules of B (), and a molecule each of A and B ()
on the receptor dimer.
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The equilibrium occupancy by ligand A (
A) in the pres-
ence of ligand B may then be derived as follows.

A 
2AR ARA 2ARB
RT

A/KA2  A/KA  2B/KB
1  A/KA2  A/KA  2B/KB
 B/KB2  B/KB
(29)
Figure 21B illustrates a series of binding curves sim-
ulated according to eq. 29. The only difference between
the curves is the degree of cooperativity () between A
and B on the receptor dimer, yet this is sufficient to
accommodate a wide range of binding profiles including
multiple affinity states and bell-shaped curves.
From the preceding discussion, it is apparent that
even the simplest scenario of a receptor dimer provides
scope for a bewildering array of allosteric interactions
occurring between orthosteric binding sites. Despite the
potential for allosteric effects arising from cooperative
binding at GPCR oligomers, however, the frequency of
such phenomena and their functional relevance are cur-
rently unclear. Certainly, more direct biochemical
and/or structural evidence of GPCR dimerization is now
becoming available, having been obtained from photoaf-
finity labeling experiments, receptor cross-linking stud-
ies, mutagenesis experiments, and the construction of
receptor chimeras (for references, see Hebert and Bou-
vier, 1998). The latter studies, in particular, have pro-
vided an impetus for much of the more recent work on
GPCR dimerization. For instance, Wess and colleagues
(Maggio et al., 1993a,b), constructed a series of 2-adre-
noceptor/M3 muscarinic receptor chimeras that con-
tained the first 5 transmembrane domains of one recep-
tor type linked to the last two of the other type of
receptor and then studied their properties in a recombi-
nant expression system. When transfected alone, nei-
ther chimera showed significant ligand binding activity.
However, when they were coexpressed, significant num-
bers of both 2 and M3 binding sites were detected.
Furthermore, this phenomenon was functionally rele-
vant, because the cotransfected cells were able to re-
spond to stimulation with a muscarinic receptor agonist.
This functional “rescue” of receptor activity on coexpres-
sion of the two different chimeric constructs could only
be explained by an intermolecular rearrangement of
transmembrane domains between the two receptor chi-
meras, thus, highlighting the possibility of GPCR-GPCR
interactions.
Further evidence of functionally relevant GPCR
dimerization has been recently provided by Bouvier and
colleagues (Hebert et al., 1996, 1998), who used a strat-
egy of differential epitope tagging to demonstrate that
the 2-adrenoceptor responds to agonist binding by
forming receptor homodimers. Importantly, a peptide
derived from TM domain VI of the 2-adrenoceptor was
able to inhibit both dimer formation and isoproterenol-
mediated adenylyl cyclase activity. This finding pro-
vided structural evidence for the TM VI interface as
being an important determinant of 2-adrenoceptor ho-
modimerization and suggesting a requisite role of the
dimerization process in 2-receptor activation. Although
originally identified in cellular membrane fragments,
2-adrenoceptor homodimerization has subsequently
been demonstrated in vivo in intact cells (Angers et al.,
2000, 2001).
From these findings, it may be concluded that GPCR
homodimerization could represent a generalized para-
digm of receptor activation. However, the -opioid recep-
tor has been found to display quite a different dimeriza-
tion profile in response to agonist stimulation (Cvejic
and Devi, 1997). Specifically, the effect of the agonist
was found to be a promotion of receptor monomers and a
decrease in receptor dimers. This agonist-mediated mo-
nomerization precedes agonist-mediated internalization
of the receptors, thus, suggesting a role for -opioid
receptor dimers in modulating the internalization pro-
cess. Interestingly, studies of bradykinin B2 receptor
dimers have found that dimer formation is required both
for agonist-mediated receptor activation and desensiti-
zation (AbdAlla et al., 1999).
Given the current paucity of detailed studies on the
functional consequences of GPCR dimerization, it is
quite likely that further studies will identify a number of
roles for the dimerization process that will be dependent
on both the nature of the dimerization mechanism and
the cellular background in which this mechanism is
operative. For example, the sensitivity of muscarinic M3
(Zeng and Wess, 1999) and -opioid (Jordan and Devi,
1999) receptor homodimers to reducing agents suggests
a role for the disulfide bonds of the extracellular receptor
loops in the mechanism of receptor dimerization. In con-
trast, other GPCRs, including the bradykinin B2 recep-
tor, the metabotropic glutamate receptor, and the extra-
cellular calcium-sensing receptor rely on their
SCHEME 3.
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N-terminal regions to form homodimers (AbdAlla et al.,
1999, and references therein). As described above, 2-
adrenoceptor homodimers require the structural integ-
rity of receptor TM region VI, whereas dopamine D2
homodimers rely on TM VI and VII (Ng et al., 1996). It
is possible that these latter types of transmembrane
interface interactions extend to other GPCRs, because
the chimeric receptor studies of Wess and colleagues
(outlined above) also suggested a role for intermolecular
interactions between transmembrane domains of 2/M3
receptor chimeras. A general model to account for this
latter type of interaction has been proposed by Gouldson
et al. (1998, 2000) and termed “domain swapping”. This
model postulates that GPCR homodimers can form by
“swapping” TM regions V and VI. The advantages of
dimer formation using this mechanism are that it is
energetically favorable, using the same type of bonding
forces that maintain the structure of a standard GPCR
monomer, and that it can minimize the effects of loss-
of-function mutations. A number of studies of “function-
al receptor rescue” have demonstrated how mutated re-
ceptors that cannot signal are able to do so when they
undergo a dimerization with another equivalent of re-
ceptor (see Gouldson et al., 1998, 2000).
GPCR dimerization does not necessarily have to be
restricted to the formation of homodimers. Some recep-
tors may need to form heterodimers to function properly.
The first discovery of this phenomenon was in relation to
the metabotropic GABAB receptor. Although cloning
studies had identified two distinct monomeric receptor
subtypes, termed the GABABR1 and GABABR2 recep-
tors (see Marshall et al., 1999), appropriate functional
responses corresponding to native receptor properties
could only be obtained when these two subtypes were
coexpressed in the same cell (Jones et al., 1998; Kaup-
mann et al., 1998; White et al., 1998). Subsequent stud-
ies have identified the GABAB heterodimer as a tightly
associated C-terminal “coiled-coil” structure that is most
likely preformed in the endoplasmic reticulum and,
therefore, does not need to be induced by agonist binding
(Marshall et al., 1999). Another recently identified ex-
ample of GPCR heterodimerization involves the combi-
nation of - and -opioid receptors (Jordan and Devi,
1999). In contrast to -opioid homodimers, --het-
erodimers display a minimal tendency to monomerize in
the presence of agonist. This suggests a role of het-
erodimerization in modulating receptor function. The
- heterodimers also display profound differences in
their ability to bind - or -selective ligands. Table 9
shows some examples of the binding properties of selec-
tive opioid ligands to the -, -, or --receptor com-
plexes. What is most striking is the enhancement of
apparent ligand affinity at the heterodimer when mea-
sured in the presence of another ligand, suggesting pos-
itive cooperativity in the mode of agonist binding to the
heterodimer. Similarly, angiotensin AT1 receptor and
bradykinin B2 receptor heterodimers display signifi-
cantly different pharmacological profiles when exposed
to the endogenous agonist for either receptor in compar-
ison to each receptor when it is individually expressed
(Fig. 22; see AbdAlla et al., 2000). Importantly, the al-
tered pharmacological responsiveness of the AT1-B2 het-
erodimer has recently been linked to the hypertension
that characterizes the condition of pre-eclampsia, which
is often observed in pregnant women (AbdAlla et al.,
2001). This is a striking example of a disease that is
mediated, at least in part, as a consequence of increased
GPCR heterodimer formation.
As with the ion channel-linked receptors, therefore, it
seems that heterodimerization of GPCRs may represent
an important mechanism for generating receptor sub-
types with a pharmacological profile that is distinct from
that of either monomer alone. In this latter instance, the
resulting, “new” pharmacological profile most likely re-
flects the extent of allosteric interaction between multi-
ple orthosteric sites within a receptor oligomer. How-
ever, the true extent of this phenomenon is far from
known and the field of GPCR oligomerization is rapidly
expanding. Further detailed discussion is beyond the
scope of this review; Table 10 summarizes studies con-
ducted on ligand regulation of GPCR oligomerization
and/or altered receptor pharmacology as a consequence
of GPCR oligomerization.
B. Accessory Proteins
In classical receptor theory, a basic tenet is the belief
that the receptor is the minimal unit required for the
production of drug response. Thus, operationally, a li-
gand combines with a receptor and produces a physio-
logical response. Implicit in this scheme is the fact that
TABLE 9
Ligand-binding properties of selected opioid ligands for the –
heterodimer
Ligand
KI (nM)
  –
U69593 14.4 1000 1000
DPDPE 1000 21.8 1000
U69593 (
 10 M DPDPE) 14.4 —a 9.2
DPDPE (
 10 M U69593) —a 24.8 20.0
a Not tested.
Data from Jordan and Devi, 1999.
FIG 22. Generation of inositol phosphaptes by angiotensin-II (left
panel) or bradykinin (right panel) in HEK 293 cells transfected individ-
ually (open symbols) or cotransfected (solid symbols) with the AT1 and B2
receptors. Receptor cotransfection generates a novel pharmacological pro-
file for either agonist. Data taken from AbdAlla et al. (2000).
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the receptor and ligand form a unique system that is
portable to all physiological arenas. In fact, this is the
basis of receptor pharmacology because it defines the
various quantitative correspondences between ligand
and effect and the relative activity of ligands, which then
allows drug discovery to be carried out in surrogate
systems and extrapolated to therapy in humans. This
concept is now being tested as recombinant systems
became widely used in experimental pharmacology. In
these experiments, receptor cDNA is transfected into
foreign host cells, and the resulting system, namely the
receptor expressed into the membrane of the host, is
used as a surrogate mimic of the receptor in its natural
environment. In general, the majority of studies confirm
this portability of receptor. However, careful observation
of the expected behavior of some receptors expressed in
some recombinant systems has uncovered anomalies
that do not conform to the idea that a receptor is always
a stand-alone entity that can be inserted into any cellu-
lar background and be expected to produce physiologi-
cally accurate behavior. These studies have provided
evidence that GPCRs are active participants in protein-
protein interactions that can often occur independently
or in conjunction with the receptor coupling to its G
protein(s) or to other receptors.
One such example has been found with 2A/D-adreno-
ceptors, which are known to couple to Gi/o proteins in
NIH-3T3 and PC-12 cells. The signal can be eliminated
by treatment with pertussis toxin and reconstituted by
addition of G protein. It was noted in these studies that
the efficiency of receptor activation differed in various
surrogate cell hosts. Specifically, the reconstitution was
3- to 9-fold greater in PC-12 cells (over NIH-3T3 cells),
and it was observed that this effect was independent of
the level of receptor expression (Nanoff et al., 1995; Sato
et al., 1995). A heat-sensitive macromolecule could be
TABLE 10
GPCR dimers/oligomers and their regulation by ligands
Receptor Reference
Ligand-regulated
Adenosine A1 Franco et al., 1996
2-adrenoceptor Gurdal et al., 1996; Hebert et al., 1996; Hebert et al., 1998; Angers et al., 2000, 2001
Bradykinin B2 AbdAlla et al., 1999
Chemokine CCR5 Vila-Coro et al., 2000
-Opioid Cvejic and Devi, 1997
GnRH receptor Cornea et al., 2001; Kroeger et al., 2001
LH receptor Roess et al., 2000
Muscarinic M2 Hirschberg and Schimerlick, 1994
TRH receptor Kroeger et al., 2001
Adenosine A1 
 Dopamine D1
a Gines et al., 2000
Somatostatin SSTR1 
 SSTR5 Rocheville et al., 2000a,b
Not ligand-regulated
-Factor Overton and Blumer, 2000
-Opioid McVey et al., 2001
Dopamine D1 George et al., 1998
Muscarinic M2 Park et al., 2001
Muscarinic M3 Zeng and Wess, 1999
Vasopressin V2 Schulz et al., 2000
 
  opioida Jordan and Devi, 1999
Regulation by ligands not determined
2-adrenoceptor Maggio et al., 1993a
AT1 angiotensin Monnot et al., 1996
1-adrenoreceptor Fowler et al., 1999
2-adrenoceptor Limbird et al., 1975; Venter and Fraser, 1983
Bradykinin B2 Pizard et al., 1998
-Opioid Polastron et al., 1994
D2 receptor Ng et al., 1996; Zawarynski et al., 1998; Scarselli et al., 2000; Armstrong and Strange,
2001; Lee et al., 2000
D3 receptor Nimchinsky et al., 1997; Karpa et al., 2000
Glucagon receptor Herberg et al., 1984
GnRH Grosse et al., 1997
Histamine Sinkins et al., 1993; Sinkins and Wells, 1993
Muscarinic Hedlund et al., 1982; Avissar et al., 1983
Muscarinic M1 Potter et al., 1988
Muscarinic M2 Mattera et al., 1985; Boyer et al., 1986; Potter et al., 1991; Wregget and Wells, 1995;
Chidiac et al., 1997
Muscarinic M3 Maggio et al., 1993b
mGluR1 Ray and Hauschild, 2000
V2 vasopressin Zhu and Wess, 1998
5-HT1B 
 5-HT1D Ng et al., 1993; Xie et al., 1999
AT1 angiotensin 
 bradykinin B2
a AbdAlla et al., 2000
Adenosine A1 
 P2Y1
a Yoshioka et al., 2001
2 
 -opioid
a Jordan et al., 2001
GABABR1 
 R2
a Kaupmann et al., 1998; White et al., 1998; Kuner et al., 1999
 
 -opioida Vaught et al., 1982; George et al., 2000; Gomes et al., 2000
mGluR1 
 adenosine A1
a Ciruela et al., 2001
a Heterodimer displays novel pharmacological properties compared with the individually expressed receptors.
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extracted from PC-12 cells that facilitated coupling of
receptor to G protein (Sato et al., 1995). Detergent sol-
ubilized membrane extracts from NG108–15 cells have
been shown to increase [35S]GTPS binding to purified
G protein by 460%. Thus, a “factor” in this system was
postulated to be a novel signal accelerator (Sato et al.,
1996). Similarly a membrane protein termed “coupling
cofactor” has been shown to trap the adenosine receptor
in the high-affinity state complexed with the G protein,
thus, reducing the catalytic activity of the receptor
(Nanoff et al., 1995, 1997). It is postulated that this
factor assists in the organization of receptor/G protein
signaling by restraining the receptor activation of some
G proteins.
Another class of monoamine agonist GPCRs known to
interact with accessory proteins are the dopamine recep-
tors. Dopamine D1 receptors preferentially signal
through Gs proteins to stimulate cAMP accumulation.
Recently, a single transmembrane-spanning protein,
termed “calcyon”, has been shown to physically associate
with D1 receptors in neurons and potentiate their ability
to stimulate intracellular calcium release, a typically
Gq/11-coupled response (Lezcano et al., 2000). Interest-
ingly, calcyon does not seem to affect D1 receptor affinity
toward dopamine agonists, which is characterized by
both high- and low-affinity components, but signifi-
cantly enhances the proportion of the high-affinity state
(Lidow et al., 2001). This finding suggests a complex
allosteric interaction involving at least three proteins,
calcyon, the D1 receptor, and its interacting G protein(s).
In addition, dopamine D2 and D3 receptors associate
with the cytoskeletal protein filamin-A, which has been
suggested to be required for proper cell surface expres-
sion of these receptors in neurons, and linking them to
downstream signaling pathways (Lin et al., 2001).
There are a number of other factors proposed to affect
the interaction between receptors and G proteins. For
example, stimulation of the chemokine CCR2B receptor
by the monocyte chemotactic protein 1 promotes the
rapid association of the receptor with the Janus kinase
2/STAT3 protein pathway. Furthermore, it has been
postulated that the association of the CCR2B receptor
with its cognate Gi protein requires the allosteric effects
induced in the receptor by both monocyte chemotactic
protein 1 binding and Janus kinase 2 association (Mel-
lado et al., 1998). In addition, the cytoskeletal protein
tubulin has been shown to affect the activation state of G
proteins (Wang et al., 1990; Roychowdhury et al., 1993;
Popova et al., 1994), and, similarly, the protein neu-
romedulin also facilitates receptor-G protein interac-
tion, possibly by accelerating the binding of cyclic nucle-
otides to G protein (Masure et al., 1986; Strittmatter et
al., 1990, 1991, 1993). Similar effects are produced by
the wasp venom mastoparan (Higashijima et al., 1988),
the -amyloid precursor protein (Okamoto et al., 1995),
and compound 48/80 (Mousli et al., 1990). Regulators of
G protein signaling proteins are also known to interfere
with receptor/G-protein coupling (Hunt et al., 1996;
Watson et al., 1996; Berman and Gilman, 1998; De Vries
et al., 2000; Zhong and Neubig, 2001).
There also are proteins known to directly affect the
activity of G proteins (Mousli et al., 1990; Strittmatter et
al., 1991; Nishimoto et al., 1993; Popova et al., 1994;
Scherer et al., 1995; Takesono et al., 1999) themselves,
but these may have no relevance to agonist profiles on
the receptors that interact with those G proteins. Simi-
larly, the cofactors discussed above may not affect the
receptor phenotype with respect to different agonists but
rather only modify the sensitivity of the receptor to all
agonists in a given system. From this standpoint, these
factors would not be relevant to the classification of
receptors and drugs or the determination of drug related
selectivity in recombinant systems, even though many of
the interactions may involve allosteric modulation of
protein-protein interactions.
In contrast, there are cofactors that seem to be di-
rectly involved in receptor phenotypic behavior toward
agonists and/or G proteins. The question then arises:
which accessory proteins affect the specific ligand/recep-
tor activity profiles of ligands thought to be the exclusive
property of ligand-receptor relationships? Furthermore,
if such accessory proteins do change the phenotype of
receptors with respect to the ligands with which they
interact, then by what manner do they do so? One idea
relates to the geometric configuration of receptor sys-
tems in membranes. For example, it can be conceived
that the organization of G protein with receptors in
microdomains may cause predisposition of receptors
that are pleiotropic with respect to G protein activation
toward a subset G proteins in certain cell types. Recep-
tors and G proteins are organized in multimeric com-
plexes that form microdomains (Neubig, 1994). The com-
bination of such organization with ligand selective
receptor active states could affect agonist profiles for
receptors in different cellular hosts. For example, a fam-
ily of proteins localized to some of these microdomains,
called caveolins, cause enrichment of these microdo-
mains with G proteins (Li et al., 1995; Scherer et al.,
1995, 1996). It is not yet known whether this results in
agonist-dependent selective receptor coupling to G pro-
teins.
A particularly well characterized case where an acces-
sory protein clearly changes the phenotype of the recep-
tor is with a family of single transmembrane proteins
required for the transport and ligand specificity termed
receptor activity modifying proteins (RAMPs). There are
three RAMPs ubiquitously distributed among tissues
and sharing approximately a 31% homology. Studies
have shown that RAMP1 associates with the calcitonin
receptor-like receptor CRLR and produces a high-affin-
ity CGRP receptor (McLatchie et al., 1998). RAMP1 also
seems to be important in controlling the translocation of
CRLR to the cell surface. Unlike RAMP1, the combina-
tion of CRLR with RAMP2 or RAMP3 does not produce
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a CGRP receptor but rather results in a receptor for
adrenomedullin. Although RAMPs have been implicated
in the trafficking of receptors to the cell membrane and
the regulation of the glycosylation pattern (McLatchie et
al., 1998; Foord and Marshall, 1999; Fraser et al., 1999),
there are effects of RAMPs, particularly RAMP3, that
cannot be explained by simple differences in receptor
expression. In fact, there is evidence to suggest that
RAMPs remain associated with receptors on the mem-
brane surface (McLatchie et al., 1998; Leuthauser et al.,
2000).
Studies with human calcitonin receptors demonstrate
striking effects of RAMPs. Cotransfection of RAMP3
with human calcitonin receptors produces a decrease in
the potency of human calcitonin and an increase in the
potency of rat amylin (Armour et al., 1999). A striking
reversal of relative potency of the agonists human calci-
tonin and rat amylin is observed with cotransfection of
RAMP3 (Fig. 23A). This effect is consistent with a
RAMP3-induced change in calcitonin receptor coupling
to G protein. However, RAMP3 also confers a change in
the potency of the peptide calcitonin antagonist AC66 for
antagonism of amylin, but not human calcitonin re-
sponses (see Fig. 23, B and C). These data suggest that
RAMP3 associates with the receptor to change its be-
havior to both agonists and antagonists (Armour et al.,
1999). A study by Christopoulos et al. (1999) indicates
that cotransfection of RAMP1 and RAMP3 produces an
increase in specific amylin binding in COS-7 cells trans-
fected with human calcitonin receptors. The binding and
functional profiles obtained with the two types of RAMP
in this study are consistent with the production of two
separate amylin-like receptors (Christopoulos et al.,
1999).
The revelation that RAMPs are sometimes required to
generate receptor phenotypes corresponding to native
receptors may be an example of a more generalized
phenomenon. For instance, the CGRP-receptor compo-
nent protein is another protein distinct from the RAMP
family that also couples directly to the CRLR together
with RAMPs to promote signal transduction (Luebke et
al., 1996; Evans et al., 2000). It is possible that accessory
proteins are required to unmask the pharmacology of
specific orphan receptors for which the gene product has
been identified but the endogenous activating ligand has
not.
Some other additions to the list of GPCR coupling
partners promise to quash the concept of the receptor-G
protein signaling hierarchy altogether. These novel cou-
pling partners encompass an ever-growing array of pro-
teins containing specific amino acid modules that allow
them to bind to complementary modules in other pro-
teins and, thus, lead to the assembly of multimeric sig-
naling complexes. One important family of targeting
proteins are the “PDZ domain-containing” proteins.
These possess a GLGF sequence and a conserved argi-
nine that can self-aggregate and/or interact with other
proteins containing a S/TxV motif or a F/Y-x-F/V/A
motif. The PDZ proteins derive their name from the
three cell-organizing proteins in which this association
was first noted, the postsynaptic density-95 protein, the
Drosophila disks large protein, and the Zona occludens
protein. Although already known to play a crucial role in
coupling to the NMDA ion channel-linked receptors and
targeting them to postsynaptic densities in neurons,
PDZ domain-containing proteins are now known to in-
teract directly with GPCRs as well. For example, the
somatostatin receptor subtype 2 couples to a PDZ do-
main-containing protein called SSTRIP, which then tar-
gets the receptors to their appropriate site of action
(Zitzer et al., 1999). In addition, all three subtypes of
5HT2 receptor contain PDZ consensus motifs in their
extreme C-terminal tails, and this motif has been impli-
cated in the coupling of these receptors to neuronal NOS
and a novel, multi-PDZ-domain protein termed MUPP1
(Ullmer et al., 1998; Manivet et al., 2000; Becamel et al.,
2001). The 2-adrenoceptor and the P2Y1 purinoceptor
also couple to a PDZ domain-containing protein known
as Na
/H
 exchange regulatory factor and are able to
regulate its function completely independent of their
ability to couple to G proteins (Hall et al., 1998a, 1998b).
Similarly, the 1-adrenoceptor couples to the postsynap-
tic density-95 protein via a similar PDZ interaction (Hu
et al., 1996, 2000).
Finally, GPCRs that contain polyproline-rich regions,
such as those found in the third intracellular loop of the
FIG 23. Effects of RAMP3 cotransfection on the effects of agonists (A)
and the antagonist AC66 (B and C) for X. laevis melanophores transiently
expressing human calcitonin receptors. A, the relative potency of rat
amylin and human calcitonin changes by a factor of 16 with a change in
the rank order of agonist potency with cotransfection of RAMP3. B, Schild
regressions for AC66. There is no change in the antagonism of responses
to human calcitonin with cotransfection of RAMP3. However, a 10-fold
loss of potency of AC66 for amylin antagonism was observed (C). Redrawn
from Armour et al. (1999).
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1-adrenoceptor, are able to bind with other targeting
proteins that contain Src homology (SH)3 domains, WW
domains, or enabled/VASP domains. The “endophilins”
(SH3p4/p8/p13) are one such group of proteins that are
able to bind to the 1-adrenoceptor and may play a role
in agonist-mediated internalization of that receptor
(Tang et al., 1999). Another example relates to members
of the metabotropic glutamate receptor family that cou-
ple to a protein known as “Homer” through a polypro-
line-rich region in the C termini of the receptors (Neu-
big, 1998; Bockaert and Pin, 1999). Interestingly,
overexpression of the mGluR1a and mGluR5 metabo-
tropic glutamate receptors in heterologous cell lines led
to agonist-independent constitutive receptor activity
and also revealed that the direct intracellular associa-
tion of different Homer proteins was sufficient to pro-
mote or silence this receptor activation (Ango et al.,
2001). In this instance, an allosteric conformational
change induced via intracellular GPCR-protein interac-
tions were shown to elicit agonist-independent signaling
that displayed different temporal patterns to agonist-
mediated signaling; this can have significant implica-
tions for events such as synaptic plasticity.
Findings such as these highlight the bewildering ar-
ray of GPCR-accessory protein interactions, but it
should be noted that many of these may prove to use
allosteric mechanisms in subserving their physiological
roles. For instance, in certain neurons, a family of lami-
nin-secreted proteins termed “netrins” controls axon
elongation. The receptor originally proposed to bind ne-
trin-1, the DCC protein, does not interact directly with
the netrin. Rather, the DCC protein associates with one
region of the adenosine A2b receptor while the netrin-1
protein associates with another region that is topo-
graphically distinct from the adenosine-binding site. To-
gether, this novel “ternary complex” mediates many of
the effects on axonal outgrowth ascribed to the netrins
(Corset et al., 2000) and suggests a novel role for A2b
receptors in the nervous system, beyond neurotransmis-
sion, that is predicated by an allosteric interaction.
VIII. Conclusions
Allosteric interactions can be manifested in a variety
of ways, but they all involve the transmission of a con-
formational change across the surface of a GPCR such
that the subsequent ability of that receptor to bind other
ligands and/or proteins is modified. Thus, allosteric
mechanisms allow for profound alterations in cellular
homeostasis in response to often subtle receptor binding
events. This review has focused on allosterism between
multiple sites within the same GPCR and interactions
between GPCRs and other proteins. Although the con-
sequences of allosteric interactions involving these re-
ceptors can vary dramatically, the study and quantifica-
tion of these phenomena often involve similar
approaches that can provide a remarkable insight into
the communication machinery of the cell. Ultimately,
the exploitation of allosteric phenomena may lead to
novel therapeutic regimens that provide maximum ben-
efit while causing minimal adverse effects. Importantly,
the study of such phenomena will become of progres-
sively greater import as the impact of newer and more
sensitive GPCR screening technologies is absorbed and
assimilated into the drug discovery process.
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